

Weekly

December 15, 2006 / Vol. 55 / No. 49

# Visual Impairment and Eye Care Among Older Adults — Five States, 2005

Blindness and visual impairment are among the 10 most common causes of disability in the United States (1) and are associated with shorter life expectancy and lower quality of life (2,3). Previously, state-specific prevalences of visual impairment and eye disease were estimated from national prevalences. However, in 2005, five states (Iowa, Louisiana, Ohio, Tennessee, and Texas) provided state-specific estimates by using the new CDC Behavioral Risk Factor Surveillance System (BRFSS) vision module. CDC analyzed data from the module to determine the self-reported prevalence of visual impairment, eye disease, eye injury, and lack of eye-care insurance and eye examination among persons aged  $\geq$  50 years in each of these five states and among certain sociodemographic populations overall. This report describes the results of that analysis, which indicated variation in disease prevalence and use of eye care among individual states and also among racial/ ethnic populations and age groups within the five states combined. The variability among state data suggests that statespecific surveillance of visual impairment and eye care and investigation by states to identify influencing factors might lead to creation of vision programs better suited to individual state needs.

BRFSS is a state-based, random-digit–dialed telephone survey of the noninstitutionalized, U.S. civilian population aged ≥18 years. The median Council of American Survey Research Organizations response rate for BRFSS in 2005 was 51.1%, with a range among states of 34.6% to 67.4%. Response rates for the five states using the optional BRFSS vision module in 2005 were as follows: Iowa, 60.2%; Louisiana, 51.4%; Ohio, 49.5%; Tennessee, 59.6%; and Texas, 45.2%. Among the five states, Louisiana provided data only for January–August because of Hurricane Katrina. Respondents were classified as having visual impairment if they answered "a little difficulty," "moderate difficulty," "extreme difficulty," or "unable to do because of eyesight" to the question, "How much difficulty, if

any, do you have in recognizing a friend across the street?" or to the question, "How much difficulty, if any, do you have watching television?"\* Three selected eye diseases (i.e., cataract, glaucoma, and macular degeneration) and workplace eye injury were identified if respondents answered "yes" to the relevant questions.<sup>†</sup> Diabetic retinopathy was identified (from the BRFSS diabetes module) if respondents with diabetes answered "yes" to the question, "Has a doctor ever told you that diabetes has affected your eyes or that you had retinopathy?"

The BRFSS vision module also incorporated questions relating to use of eye care. Respondents were classified as not having eye insurance if they answered "no" to the question, "Do you have any kind of health insurance coverage for eye care?" Respondents were classified as not having had a dilated eye examination in the preceding 12 months if they answered other than "within the past month" or "within the past year (1–12 months ago)" to the question, "When was the last time you had an eye exam in which the pupils were dilated?" They were classified as not having visited an eye-care professional in the preceding 12 months if they answered other than "within here with the pupils were dilated?" They were classified as not having visited an eye-care professional in the preceding 12 months if they answered other than "within

## INSIDE

- 1325 Public Health Surveillance for Smallpox United States, 2003–2005
- 1327 Immunization Information Systems Progress United States, 2005
- 1329 Influenza Vaccination Coverage Among Children Aged 6–23 Months — Six Immunization Information System Sentinel Sites, United States, 2005–06 Influenza Season
- 1331 QuickStats

<sup>\*</sup> While wearing glasses or contact lenses, for those who wore them.

<sup>&</sup>lt;sup>†</sup> "Have you been told by an eye doctor or other health-care professional that you now have cataracts?" "Have you ever been told by an eye doctor or other health-care professional that you had glaucoma?" "Have you ever been told by an eye doctor or other health-care professional that you had macular degeneration?" "Have you ever had an eye injury that occurred at your workplace while you were doing your work?"

The *MMWR* series of publications is published by the Coordinating Center for Health Information and Service, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

**Suggested Citation:** Centers for Disease Control and Prevention. [Article title]. MMWR 2006;55:[inclusive page numbers].

### **Centers for Disease Control and Prevention**

Julie L. Gerberding, MD, MPH *Director* Tanja Popovic, MD, PhD (*Acting*) Chief Science Officer

James W. Stephens, PhD (Acting) Associate Director for Science

Steven L. Solomon, MD Director, Coordinating Center for Health Information and Service Jay M. Bernhardt, PhD, MPH Director, National Center for Health Marketing Judith R. Aguilar

(Acting) Director, Division of Health Information Dissemination (Proposed)

#### **Editorial and Production Staff**

John S. Moran, MD, MPH (Acting) Editor, MMWR Series Suzanne M. Hewitt, MPA

Managing Editor, MMWR Series Douglas W. Weatherwax (Acting) Lead Technical Writer-Editor

Catherine H. Bricker, MS Jude C. Rutledge Writers-Editors

Beverly J. Holland Lead Visual Information Specialist Lynda G. Cupell Malbea A. LaPete

Visual Information Specialists Quang M. Doan, MBA

Erica R. Shaver Information Technology Specialists

#### **Editorial Board**

William L. Roper, MD, MPH, Chapel Hill, NC, Chairman Virginia A. Caine, MD, Indianapolis, IN David W. Fleming, MD, Seattle, WA William E. Halperin, MD, DrPH, MPH, Newark, NJ Margaret A. Hamburg, MD, Washington, DC King K. Holmes, MD, PhD, Seattle, WA Deborah Holtzman, PhD, Atlanta, GA John K. Iglehart, Bethesda, MD Dennis G. Maki, MD, Madison, WI Sue Mallonee, MPH, Oklahoma City, OK Stanley A. Plotkin, MD, Doylestown, PA Patricia Quinlisk, MD, MPH, Des Moines, IA Patrick L. Remington, MD, MPH, Madison, WI Barbara K. Rimer, DrPH, Chapel Hill, NC John V. Rullan, MD, MPH, San Juan, PR Anne Schuchat, MD, Atlanta, GA Dixie E. Snider, MD, MPH, Atlanta, GA John W. Ward, MD, Atlanta, GA

the past month" or "within the past year" to the question, "When was the last time you visited any eye-care professional?" In addition, respondents were asked the main reason they had not visited an eye-care professional in the preceding 12 months. The analyses were weighted to make estimates representative of the civilian, noninstitutionalized population in the five states.

A total of 13,931 responses<sup>§</sup> were analyzed using statistical software to account for the survey design complexity. Trends were assessed using linear regression by the weighted least squares method.

The self-reported prevalence of visual impairment and eye disease among persons aged  $\geq$  50 years varied among the five states that used the BRFSS vision module in 2005. The prevalence of visual impairment ranged from 14.3% (95% confidence interval [CI] = 12.9%-15.8%) in Iowa to 20.5% (CI = 18.6%-22.5%) in Ohio (Table 1). Prevalence of cataract ranged from 29.0% (Texas) to 34.3% (Iowa), prevalence of glaucoma ranged from 5.0% (Tennessee) to 7.4% (Louisiana), prevalence of macular degeneration ranged from 3.1% (Tennessee) to 5.4% (Iowa), and prevalence of diabetic retinopathy ranged from 2.7% (Ohio) to 4.3% (Louisiana). The self-reported prevalence of workplace eye injury history ranged from 5.8% (Tennessee) to 9.0% (Iowa) among the five states. With the exception of diabetic retinopathy, women had higher prevalence of visual impairment and eye disease than men. Among age groups, prevalence of cataract and glaucoma increased with age, and prevalence of workplace eye injury history decreased with age (p<0.05).

Having eye-care insurance and use of eye care also varied among the five states (Table 2). The percentage of participants reporting no eye-care insurance ranged from 46.2% (Ohio) to 55.0% (Tennessee). In addition, the percentage reporting they had not had a dilated eye examination during the preceding 12 months ranged from 40.6% (Iowa) to 46.2% (Texas); the percentage reporting no visit to an eye-care professional in the preceding 12 months ranged from 30.4% (Iowa) to 34.8% (Texas). Persons in the five states cited "no reason to go" (range: 42.8% in Louisiana to 60.9% in Iowa) and "cost/insurance" (range: 18.5% in Ohio to 22.1% in Tennessee) as the most common reasons for not having visited an eye-care professional in the preceding 12 months. Overall, persons aged 50-59 years were least likely to report not having eye-care insurance. The percentage of persons who had not had a dilated eye examination or a visit to an eye-care professional in the preceding 12 months decreased with increasing age (p < 0.05). Men were more likely than women to report not having had a dilated eye examination or not having had an eye-care visit.

<sup>&</sup>lt;sup>§</sup> Iowa, 2,749; Louisiana, 1,440; Ohio, 3,967; Tennessee, 2,565; and Texas, 3,210.

	in	Visual pairment	Cat	aract <sup>+</sup>	Gla	aucoma§	deg	Macular jeneration <sup>1</sup>	D retir	iabetic lopathy**	V e	Vorkplace ye injury††
State/Characteristic	%	(95% Cl <sup>§§</sup> )	%	(95% CI)	%	(95% CI)	%	(95% CI)	%	(95% CI)	%	(95% CI)
lowa	14.3	(12.9–15.8)	34.3	(32.4–36.3)	5.9	(5.0-7.0)	5.4	(4.5-6.4)	3.0	(2.4–3.8)	9.0	(7.8–10.4)
Louisiana <sup>¶¶</sup>	17.7	(15.5-20.1)	30.1	(27.5-32.8)	7.4	(6.1–9.1)	3.7	(2.8-4.9)	4.3	(3.3-5.7)	6.6	(5.2-8.4)
Ohio	20.5	(18.6-22.5)	30.0	(27.9-32.3)	5.2	(4.3-6.3)	3.8	(3.0-4.7)	2.7	(2.1 - 3.5)	7.0	(5.8-8.5)
Tennessee	17.0	(15.2–18.9)	30.2	(28.0-32.5)	5.0	(4.1–6.2)	3.1	(2.4-4.0)	3.8	(2.9-5.1)	5.8	(4.7-7.1)
Texas	19.8	(18.1–21.5)	29.0	(27.1–30.9)	6.9	(5.9–8.0)	4.7	(3.9–5.6)	3.9	(3.2–4.8)	7.2	(6.1–8.6)
Age (yrs)												
50–59	17.9	(16.3–19.5)	9.9***	(8.7–11.1)	3.4***	(2.7-4.1)	1.6	(1.2-2.2)	3.2	(2.5–3.9)	8.7**	** (7.5–10.0)
60–69	18.0	(16.3–19.7)	29.2	(27.2–31.2)	5.8	(4.8-6.9)	2.9	(2.3–3.7)	4.2	(3.4–5.2)	7.9	(6.7–9.3)
70–79	20.2	(18.2–22.3)	56.9	(54.4–59.4)	9.2	(7.9–10.8)	6.4	(5.3–7.7)	4.0	(3.1–5.0)	4.3	(3.3–5.5)
<u>≥</u> 80	24.7	(21.8–27.9)	66.8	(63.3–70.1)	13.4	(11.1–16.1)	15.3	(12.7–18.3)	2.5	(1.7–3.7)	3.0	(1.8–4.8)
Sex												
Male	16.0	(14.6–17.5)	24.4	(22.8-26.1)	4.9	(4.1–5.7)	3.5	(2.9-4.3)	3.5	(2.9-4.3)	13.0	(11.6-14.4)
Female	21.5	(20.3–22.8)	34.6	(33.2–36.0)	7.2	(6.4–8.1)	4.8	(4.2–5.4)	3.6	(3.1–4.2)	2.1	(1.7–2.5)
Race/Ethnicity												
White, non-Hispanic	17.7	(16.7–18.8)	30.8	(29.6-32.0)	5.3	(4.8-5.9)	4.3	(3.8-4.9)	2.5	(2.2-3.0)	7.1	(6.4-7.9)
Black, non-Hispanic	23.2	(20.0–26.9)	25.1	(21.9–28.6)	10.2	(8.2–12.7)	2.5	(1.6–3.9)	8.0	(5.9–10.8)	4.0	(2.8–5.6)
Other race	22.0	(16.8-28.2)	29.2	(23.2-35.9)	5.7	(3.6-8.8)	6.3	(3.7-10.6)	4.1†††	(2.2 - 7.4)	10.9	(7.2 - 16.0)
Hispanic	25.8	(21.4–30.6)	25.4	(21.3–30.1)	10.3	(7.5–14.0)	3.8	(2.3–6.2)	8.7	(6.3–11.8)	7.5	(4.8–11.5)
Education												
Less than high school	28.4	(25.6-31.4)	38.0 <sup>§§§</sup>	(35.0-41.1)	10.0	(8.1–12.2)	5.3	(4.1-6.9)	5.8 <sup>§§§</sup>	(4.6-7.4)	8.8	(7.0–10.9)
High school graduate	20.2	(18.5–21.9)	31.8	(29.9–33.7)	6.2	(5.2–7.2)	3.9	(3.3-4.7)	4.3	(3.6–5.2)	7.9	(6.7–9.2)
More than high school	15.5	(14.3–16.7)	26.5	(25.1–28.0)	5.0	(4.4–5.8)	4.1	(3.5–4.8)	2.4	(1.9–3.0)	6.1	(5.2–7.0)
Annual household incom	е											
<\$15,000	31.9 <sup>¶¶</sup>	¶ (28.8–35.3)	39.1 <sup>¶¶¶</sup>	(35.9–42.5)	10.7 <sup>¶¶</sup>	◎ (8.8–13.0)	6.0 <sup>¶</sup>	<sup>III</sup> (4.7–7.7)	5.8 <sup>¶¶¶</sup>	(4.5–7.6)	9.1	(7.0–11.7)
\$15,000-\$24,999	23.4	(21.0-26.1)	37.8	(35.1–40.6)	8.1	(6.8–9.8)	5.6	(4.6-6.9)	5.0	(3.9–6.5)	7.3	(5.8–9.1)
\$25,000-\$34,999	18.9	(16.3-21.7)	34.8	(31.5–38.1)	6.1	(4.7-7.9)	4.8	(3.4-6.6)	3.6	(2.6–5.1)	8.7	(6.5–11.5)
\$35,000-\$49,999	17.3	(15.0–19.9)	25.8	(23.0–28.7)	5.0	(3.6–6.7)	3.6	(2.6-5.1)	2.4	(1.5–3.7)	8.9	(7.0–11.1)
≥\$50,000	12.8	(11.4–14.4)	17.5	(15.8–19.3)	2.9	(2.3–3.7)	1.8	(1.3–2.4)	2.0	(1.5–2.8)	6.0	(5.0–7.3)

TABLE 1. Prevalence of self-reported visual impairment,\* selected eye diseases, and workplace eye injury history among persons aged  $\geq$ 50 years, by state and selected demographic characteristics — Behavioral Risk Factor Surveillance System, five states, 2005

\* Respondents were classified as having visual impairment if they answered "a little difficulty," "moderate difficulty," "extreme difficulty," or "unable to do because of eyesight" to the question: "How much difficulty, if any, do you have in recognizing a friend across the street?" or to the question, "How much difficulty, if any, do you have watching television?"

<sup>†</sup> Respondents were classified as having cataract if they answered "yes" or "yes, but had them removed" to the question: "Have you been told by an eye doctor or other healthcare professional that you now have cataracts?"

§ Respondents were classified as having glaucoma if they answered "yes" to the question: "Have you ever been told by an eye doctor or other health-care professional that you had glaucoma?"

<sup>1</sup> Respondents were classified as having macular degeneration if they answered "yes" to the question: "Have you ever been told by an eye doctor or other health-care professional that you had macular degeneration?"

\*\* Respondents were classified as having diabetic retinopathy if they answered "yes" to the question: "Has a doctor ever told you that diabetes has affected your eyes or that you had retinopathy?"

<sup>††</sup> Respondents were classified as having had a workplace eye injury if they answered "yes" to the question: "Have you ever had an eye injury that occurred at your workplace while you were doing your work?"

§§ Confidence interval.

<sup>¶</sup> Because of Hurricane Katrina, Louisiana provided data only for January–August.

\*\*\* The prevalence of cataract and glaucoma increased and the prevalence of workplace eye injury history decreased with increasing age (p<0.05).

ttt Estimates with a relative standard error >30%. These estimates are considered statistically unreliable and should be interpreted with caution.

SSS The prevalence of cataract and diabetic retinopathy decreased as education level increased (p<0.05).

The prevalence of visual impairment and eye disease decreased as income level increased (p<0.05).

Having eye-care insurance and use of eye care also varied by race/ethnicity, education, and income (p<0.05). Hispanics were more likely than non-Hispanic whites to report not having eye-care insurance, not having had a dilated eye examination, and not having had an eye-care visit during the preceding 12 months. Respondents with less than a high school education or annual household income <\$15,000 were least likely to use eye-care services. Moreover, the percentage without eye-care insurance decreased as education and income levels increased (p<0.05).

**Reported by:** *RN Bailey, OD, College of Optometry, Univ of Houston, Texas. RW Indian, MS, Bur of Health Surveillance — Prevention, Ohio Dept of Health. X Zhang, MD, PhD, LS Geiss, MS, MR Duenas, OD,* 

JB Saaddine, MD, Div of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, CDC.

**Editorial Note:** This report is the first to provide statespecific estimates of the self-reported prevalence of visual impairment, eye disease, and use of eye-care services. The varied prevalences among states suggest needs for state-level surveillance of visual impairment and investigation of potential barriers to eye care to enable development of vision-loss prevention and eye-health promotion programs tailored to individual state needs.

Approximately half of those who did not visit an eye-care professional during the preceding 12 months said they had no reason to go. The lack of concern regarding the need for

	No	eve-care	No	dilated	No vi	sit to an <sup>§</sup>		Reason for r	no eye-care v	∕isit¹
	ins	urance*	eye ex	amination <sup>†</sup>	eye-care	professional	No rea	ason to go	Cost/Ir	nsurance
State/Characteristic	%	(95% CI**)	%	(95% CI)	%	(95% CI)	%	(95% CI)	%	(95% CI)
lowa	51.8	(49.7–53.9)	40.6	(38.3–42.9)	30.4	(28.5–32.4)	60.9	(57.0–64.6)	20.3	(17.4–23.6)
Louisiana <sup>††</sup>	50.5	(47.5–53.5)	41.7	(38.3–45.1)	32.0	(29.2-34.9)	42.8	(37.5–48.2)	20.3	(16.4–24.9)
Ohio	46.2	(43.8–48.7)	43.3	(40.6-46.1)	33.1	(30.8-35.4)	55.6	(51.2–59.9)	18.5	(15.4–22.0)
Tennessee	55.0	(52.4–57.6)	42.7	(39.9–45.5)	31.2	(28.9–33.6)	48.1	(43.6–52.7)	22.1	(18.6–26.0)
Texas	52.5	(50.3–54.6)	46.2	(43.8–48.6)	34.8	(32.7–36.9)	49.8	(46.0–53.6)	20.0	(17.1–23.2)
Age (yrs)										
50–59	46.8	(44.8–48.9)	52.7 <sup>§§</sup>	(50.4–54.9)	39.8 <sup>§§</sup>	(37.8–41.8)	47.0 <sup>¶¶</sup>	(43.6–50.3)	22.9	(20.3–25.7)
60–69	55.3	(53.1–57.6)	43.9	(41.4–46.4)	33.2	(31.1–35.3)	53.4	(49.5–57.2)	22.4	(19.3–25.8)
70–79	52.8	(50.3–55.4)	32.1	(29.5–34.9)	25.0	(22.8–27.3)	57.7	(52.5–62.8)	10.7	(7.8–14.6)
<u>≥</u> 80	53.1	(49.5–56.7)	29.2	(25.7–33.1)	20.7	(17.9–23.9)	62.7	(54.8–70.1)	5.7***	(3.1–10.4)
Sex										
Male	49.3	(47.2–51.3)	48.5	(46.2-50.8)	38.2	(36.2-40.2)	58.9	(55.4-62.2)	14.4	(12.1–17.0)
Female	52.3	(50.8–53.8)	40.4	(38.8–42.1)	29.1	(27.8–30.5)	42.9	(40.2–45.7)	26.0	(23.6–28.6)
Race/Ethnicity										
White, non-Hispanic	50.7	(49.4–52.1)	43.3	(41.8–44.8)	32.7	(31.4-33.9)	54.8	(52.4–57.2)	16.7	(15.0–18.4)
Black, non-Hispanic	43.9	(39.8-48.1)	47.0	(42.0-52.1)	33.2	(29.3-37.3)	41.9	(34.8-49.2)	27.5	(21.2-34.8)
Other race	43.8	(36.5-51.4)	44.3	(35.9–53.0)	36.7	(29.4-44.8)	42.0	(29.2-56.0)	26.0	(15.4–40.4)
Hispanic	63.2	(57.9–68.2)	52.3	(45.8–58.7)	38.5	(33.3–43.9)	34.7	(27.0–43.4)	35.9	(27.9–44.7)
Education										
Less than high school	64.5†††	(61.4–67.5)	52.6	(48.8-56.4)	41.6	(38.4-45.0)	38.9	(33.9-44.0)	31.5 <sup>§§§</sup>	(26.7-36.7)
High school graduate	54.5	(52.4-56.7)	44.4	(42.1-46.8)	33.3	(31.3-35.3)	51.2	(47.5-54.9)	22.1	(19.3-25.3)
More than high school	44.8	(43.1-46.5)	41.8	(40.0-43.7)	30.8	(29.2-32.5)	56.5	(53.2–59.7)	13.5	(11.5–15.8)
Annual household income										
<\$15,000	67.1†††	(63.7–70.3)	50.4	(46.4–54.4)	39.1	(35.8–42.5)	35.2 <sup>¶¶</sup>	(30.3-40.4)	43.4 <sup>§§§</sup>	(37.9–49.1)
\$15,000-\$24,999	59.8	(56.9-62.7)	43.9	(40.6-47.3)	34.0	(31.3-36.8)	41.6	(36.9-46.5)	31.4	(26.8-36.4)
\$25,000-\$34,999	49.7	(46.1–53.3)	44.4	(40.4–48.4)	32.5	(29.1–36.2)	57.4	(50.4–64.1)	18.1	(13.8–23.2)
\$35,000–\$49,999	46.5	(43.1–49.9)	45.5	(41.9–49.2)	33.7	(30.5–37.0)	54.3	(48.2–60.1)	13.7	(10.3–18.1)
≥\$50,000	40.4	(38.0-42.7)	43.8	(41.3–46.4)	32.3	(30.0–34.6)	61.9	(57.6–66.0)	6.4	(4.7–8.7)

TABLE 2. Prevalence of no eye-care insurance, no dilated eye examination, and no visit to an eye-care professional among persons aged >50 years, by state and selected demographic characteristics — Behavioral Risk Factor Surveillance System, five states, 2005

Respondents who had no health insurance coverage for eve care.

Respondents who had not had a dilated eye examination in the preceding 12 months.

Respondents who had not visited an eye-care professional in the preceding 12 months.

Respondents were asked the main reason they had not visited an eye-care professional in the preceding 12 months. The two most cited reasons were "no reason to go" and "cost/insurance."

Confidence interval

**††** Because of Hurricane Katrina, Louisiana provided data only for January-August.

The percentage of persons with no dilated eye examination or visit to an eye-care professional in the preceding 12 months decreased with increasing age (p<0.05).

The percentage of persons citing "no reason to go" increased with increasing age and increasing income (p<0.05).

Estimates with a relative standard error >30%. These estimates are considered statistically unreliable and should be interpreted with caution. ttt The percentage of persons not having eye-care insurance decreased as education and income levels increased (p<0.05).

§§§

The percentage of persons citing "cost/insurance" decreased as education and income level increased (p<0.05).

preventive eye care remains a major public health concern. Early detection and timely treatment can prevent visual impairment and progression of conditions leading to blindness. An annual dilated eye examination is recommended for persons with diabetes or aged  $\geq 65$  years (4); by comparison, approximately 44% of those aged 60-69 years and 32% of those aged 70–79 years had not had a dilated eye examination during the preceding 12 months. Many eye problems are asymptomatic initially, and regular eye examinations can help delay or limit the progression of vision loss and eye diseases (5). In addition, efficacious and cost-effective strategies to detect and treat certain eye diseases exist (6-9). However, in this study, approximately 41%-46% of respondents aged  $\ge 50$ years had not had a dilated eye examination, and approximately 30%-35% had not visited an eye-care professional during the preceding 12 months. The finding that prevalence of workplace eye injury history decreased with increasing age appears counterintuitive and suggests a need for further study.

This report is subject to at least three limitations. First, the prevalences of visual impairment and eye diseases are selfreported and might be different than objective clinical measurements. Second, the data are collected by telephone survey and might not be representative of persons without landline telephones. Finally, institutionalized populations (e.g., nursing home residents) are not included in BRFSS.

CDC provides resources and technical assistance to state health departments to increase surveillance of visual impairment and eye diseases. The new BRFSS vision module can be used to help public health agencies plan, implement, and evaluate programs on vision-loss prevention and eye-health promotion at national, state, and local levels and can help monitor Healthy People 2010 objectives regarding eye care. These data can enable CDC and states to better assess the need for eye care, identify groups at high risk for eye disease, reduce health disparities, allocate scarce resources, and target effective intervention activities.

### References

- CDC. Prevalence of disabilities and associated health conditions among adults—United States, 1999. MMWR 2001;50:120–5.
- McCarty CA, Nanjan MB, Taylor HR. Vision impairment predicts 5 year mortality. Br J Ophthalmol 2001;85:322–6.
- Vu HT, Keeffe JE, McCarty CA, Taylor HR. Impact of unilateral and bilateral vision loss on quality of life. Br J Ophthalmol 2005;89:360–3.
- American Academy of Ophthalmology. Preferred practice pattern: comprehensive adult medical eye evaluation. San Francisco, CA: American Academy of Ophthalmology; 2005. Available at http://www.aao.org/ education/library/ppp/upload/comprehensive\_adult\_medical\_eye\_ exam.pdf.
- 5. Sloan FA, Picone G, Brown DS, Lee PP. Longitudinal analysis of the relationship between regular eye examinations and changes in visual and functional status. J Am Geriatr Soc 2005;53:1867–74.
- Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417–36.
- 7. Busbee BG, Brown MM, Brown GC, Sharma S. Incremental costeffectiveness of initial cataract surgery. Ophthalmology 2002;109: 606–12.
- Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. Ophthalmology 1991;98:766–85.
- 9. Javitt JC, Aiello LP, Chiang Y, Ferris FL III, Canner JK, Greenfield S. Preventive eye care in people with diabetes is cost-saving to the federal government: implications for health-care reform. Diabetes Care 1994;17:909–17.

## Public Health Surveillance for Smallpox — United States, 2003–2005

In June 1987, nearly 10 years after the World Health Organization (WHO) declared smallpox eradicated, the Council of State and Territorial Epidemiologists (CSTE) recommended removal of smallpox, a highly contagious viral disease, from the National Notifiable Diseases Surveillance System (NNDSS) (1).\* However, the attacks of September 11, 2001, raised concern that smallpox (variola) virus, might exist in laboratories other than two WHO-designated repositories and could be used as an agent of biologic terrorism (2). In response to this concern, CSTE and CDC recommended in June 2003 that smallpox again be made reportable through NNDSS and that all states, territories, and cities add smallpox to their lists of reportable diseases (3). In 2005, CSTE conducted a cross-sectional survey in the United States and its territories to assess key components for surveillance of suspected smallpox disease, including legal reporting requirements, laboratory testing, and training and education (e.g., oral presentations and guides). This report summarizes the results of that survey, which indicated that 100% had the capacity to receive and investigate reports, 94% of states had legal requirements to report suspected smallpox disease, 70% had mandatory laboratory reporting of results indicative of smallpox disease, and 68% were providing ongoing training and education of health-care providers and public health staff.

During August–October 2005, CSTE sent an e-mail to all state epidemiologists asking them to participate in the survey, which was available online to all 50 states, the District of Columbia (DC), eight U.S. territories, and health departments of nine large cities. A total of 46 states and DC (92%), one territory (13%), and seven large cities (78%) responded to the survey, for an overall response rate of 81%. The survey respondents were senior-level epidemiologists.

Forty-three of the 46 responding states and DC (94%) and all seven cities indicated having reporting requirements and other components of a surveillance system to detect suspected smallpox disease. In addition, 25 states and DC (55%) and four cities (57%) required reporting of varicella (chickenpox), a potentially severe vesicular or pustular rash illness with certain signs and symptoms similar to smallpox. Participants also reported that other surveillance systems were in place to detect suspected smallpox disease, including 1) syndromic surveillance in 33 states and DC (72%) and six cities (86%) and 2) rash illness surveillance in 29 states and DC (64%) and four cities (57%).

All 55 respondents reported having the capacity to receive and investigate reports of suspected smallpox disease 24 hours a day and 7 days a week. Forty-one states and DC (89%) had the capacity to receive disease reports primarily by telephone and 33 (70%) primarily by fax. Fifteen (32%) respondents indicated the capacity to receive reports by e-mail and 13 (28%) via the Internet. Of the 46 responding states and DC, 42 (89%) had the ability to investigate reports by telephone, 38 (81%) by e-mail, 33 (70%) by other methods, and 31 (66%) by fax. Field or home visits were reported as the methods least likely to be used for investigation of persons with suspected smallpox (12 [26%] of 46 respondents). For the seven large cities, the patterns for receiving and investigating reports were similar.

For tests related to orthopoxviruses, including smallpox virus, 31 states and DC (68%) reported they would use the CDC laboratory; 30 (64%) would use a state health laboratory, 10 (21%) a neighboring state laboratory, four (9%) another laboratory, and three (6%) an academic facility. Twenty-six states and DC (57%) reported their state public health laboratory could rapidly provide testing by orthopoxvirus nonvariola polymerase chain reaction (PCR)

<sup>\*</sup> Decisions to include or exclude a disease from NNDSS are based on the extent of its associated morbidity and mortality and on its amenability to intervention and control.

assay and viral culture<sup>†</sup>; 22 (47%) could provide testing by orthopoxvirus PCR assay, 10 (21%) by a variola PCR assay, and seven (15%) by electron microscopy.

During 2004, an estimated 69,000 health-care and public health practitioners were trained in smallpox clinical presentation, diagnosis, and surveillance during pre-event and postevent periods by state, territorial, and large-city public health agencies. The primary means for training included presentations (58%) or using CDC materials (56%). An average of 7.8 training sessions (median: two; range: 0–133) were offered by a state public health agency, and 10.4 sessions (median: three; range: 0–116) were offered by local and county public health agencies. Professionals targeted for training were primarily public health personnel (64%), hospital emergency department staff members (44%), and other hospital staff members (45%).

**Reported by:** J Abellera, MPH, J Lemmings, MPH; CSTE Smallpox Working Group, Council of State and Territorial Epidemiologists. GS Birkhead, MD, New York State Dept of Health. SS Hutchins, MD, DrPH, National Center for Immunization and Respiratory Diseases (proposed), CDC.

Editorial Note: As with any notifiable disease, legal requirements for mandatory reporting of smallpox are necessary for complete and timely reporting of suspected or confirmed cases (4,5). These legal requirements are the foundation for statebased surveillance in the event of a terrorist attack, specifically for smallpox and other agents of biologic terrorism (i.e., Category A, B, and C agents as defined by CDC) (6). Most states also have general authority to collect data on matters of public health importance, disease outbreaks, or unusual or unforeseen occurrences (7,8). State reporting requirements, including laboratory reporting requirements, constitute a core set of components for smallpox-specific surveillance that can detect disease quickly and lead to rapid case investigation (9). These components are coupled with increased ability of terrorism-preparedness programs in states to receive and investigate reports, conduct key syndromic or other surveillance to detect smallpox, and conduct ongoing education and training sessions on smallpox recognition and disease surveillance.

Several factors have contributed to the ability of state health departments to conduct surveillance and respond to suspected

smallpox cases. States can mandate reporting by hospitals, laboratories, physicians, and other health entities for a disease within their jurisdiction. In October 2005, CSTE updated its annual NNDSS Queriable Database and noted that smallpox was reportable by law in 46 states and DC (7). Since then, two of the four states in the database that had not indicated smallpox was a reportable condition now have listed it as one of the state's notifiable diseases. The other two states report outbreaks of any kind or an unusual number of cases of any infectious disease, including smallpox.

Increases in federal funds also have affected state preparedness programs. During 2002–2005, state and local health departments received nearly \$3.5 billion in federal funds to bolster state public health preparedness programs. The funds were used in part to strengthen surveillance capacity related to agents of biologic terrorism. Increased funding in terrorism preparedness and emergency response also has increased the number of epidemiologists and increased the capacity for state-level preparedness (9). Furthermore, a greater percentage of states reported substantial to full capacity to monitor health status and to identify and investigate health problems and health hazards in communities (9).

Current reporting requirements and surveillance systems, access to laboratory facilities and modes of communication to receive information, and training of public health professionals and health-care practitioners have enhanced the public health system's capacity for responding to suspected cases of smallpox disease. The findings from the CSTE survey indicate that, in the event of suspected smallpox, the public health infrastructure has components in place to detect, receive reports of, investigate, and confirm or rule out the disease. Given that states have addressed the legal and infrastructure requirements necessary to report smallpox, continued measures should focus on the advancement of 1) reported data from physicians, laboratories, and hospitals to a public health agency, and 2) early-event-detection systems to detect suspected smallpox disease. Finally, because clinicians typically are the first to identify and diagnose disease (10), measures should focus on dissemination of educational and training materials to health-care providers, emergency medical services personnel, and public health practitioners.

#### References

- 1. Council of State and Territorial Epidemiologists. Removal of smallpox, relapsing fever and fleaborne typhus fever from the list of nationally notifiable diseases. Position statement 1987-5. Available at http://www.cste.org/PS/1987/1987-05.htm.
- 2. CDC. National vaccination strategy for smallpox outbreak containment. Available at http://www.bt.cdc.gov/agent/smallpox/response-plan.
- 3. Council of State and Territorial Epidemiologists. Smallpox surveillance. Available at http://www.cste.org/ps/2003pdfs/2003finalpdf/03-id-03 revised42004.pdf.

<sup>&</sup>lt;sup>†</sup> Certain states indicated that their state public health laboratory could perform a viral culture; however, viral culture for variola virus is not recommended for patients with suspicious rash illness, and such a procedure should be conducted only in a designated Biosafety Level 4 laboratory because of the increased risk to unvaccinated laboratory personnel. CDC/Association of Public Health Laboratories guidelines for suspected smallpox and specimen handling are available at http://www.bt.cdc.gov/agent/smallpox/diagnosis/riskalgorithm and http://www.bt.cdc.gov/agent/smallpox/diagnosis/rashtestingprotocol.asp.

- 4. Roush S, Birkhead G, Koo D, Cobb A, Fleming D. Mandatory reporting of diseases and conditions by health care professionals and laboratories. JAMA 1999;282:164–70.
- Horton HH, Misrahi JJ, Mathews GW, Kocher PL. Critical biological agents: disease reporting as a tool for determining bioterrorism preparedness. Available at: http://www2.cdc.gov/phlp/docs/cdc.horton. web.pdf.
- CDĈ. Bioterrorism agents/disease. Available at: http://www.bt.cdc.gov/ agent/agentlist-category.asp.
- Council of State and Territorial Epidemiologists. 2001 NNDSS queriable database. Available at http://www.cste.org/nndsstest6.asp.
- Council of State and Territorial Epidemiologists. 2005 NNDSS queriable database. Available at http://www.cste.org/nndsssurvey/ 2004nndss/nndss2005.asp.
- Council of State and Territorial Epidemiologists. 2004 epidemiology capacity assessment: findings and recommendations. Available at http:/ /www.cste.org/assessment/eca/pdffiles/ecafinal05.pdf.
- Woods R, McCarthy T, Barry MA, Mahon B. Diagnosing smallpox: would you know it if you saw it? Biosecur Bioterror 2004;2:157–63.

## Immunization Information Systems Progress — United States, 2005

Immunization registries are confidential, computerized information systems that collect and consolidate vaccination data from multiple health-care providers, generate reminder and recall notifications, and assess vaccination coverage within a defined geographic area (1,2). A registry with added capabilities, such as vaccine management, adverse event reporting, lifespan vaccination histories, and linkages with electronic data sources, is called an immunization information system (IIS) (3). This report summarizes data from CDC's 2005 Immunization Information System Annual Report (IISAR), a survey of grantees in 50 states, five cities,<sup>†</sup> and the District of Columbia (DC) that receive funding under section 317b of the Public Health Service Act. These data indicated that approximately 56% of U.S. children aged <6 years participated in an IIS, an increase from 48% in 2004. Moreover, 75% percent of public vaccination provider sites and 44% of private vaccination provider sites submitted vaccination data to an IIS during July-December 2005. These findings underscore the need to increase the number of participating children, from the current 13 million to approximately 21 million, to assure 95% participation of children aged <6 years and improve the effectiveness of U.S. immunization programs.

The 2005 IISAR, a self-administered, Internet-based questionnaire, was available to immunization program managers as part of an annual reporting requirement. As in previous years, respondents were asked about the number of children aged <6 years participating in the IIS, the number of healthcare provider sites participating in the IIS, and other programmatic and technical capabilities (e.g., data linkages with other public health programs, data use, vaccine management, software and hardware capabilities, and reporting functions). All 56 grantees were asked to complete the questionnaire; 52 reported on the number of children aged <6 years participating in an IIS. Estimates of the total number of children aged <6 years were based on 2005 U.S. census data.

The findings indicated that, of approximately 23 million U.S. children aged <6 years, an estimated 13 million (56%) participated in an IIS. Eleven (20%) IIS grantees (Alabama, Arkansas, Arizona, Delaware, Michigan, Mississippi, New York City, North Dakota, Oregon, Philadelphia, and Wisconsin) had >95% of children aged <6 years participating in an IIS (Figure). Eleven (20%) other IIS grantees (DC, Idaho, Iowa, Louisiana, Missouri, Montana, Oklahoma, Rhode Island, Tennessee, Utah, and Washington) had participation ranging from 81% to 94%.

Approximately 75% of public vaccination provider sites and 44% of private vaccination provider sites submitted vaccination data to an IIS during July–December 2005.<sup>§</sup> Twentytwo (39%) grantees reported that >95% of public vaccination

<sup>§</sup>Number of provider vaccination sites (public and private) is based on grantee self-reports.

FIGURE. Percentage of children aged <6 years participating\* in a grantee<sup>†</sup> immunization information system — United States, five cities, and the District of Columbia (DC),<sup>§</sup> 2005



**SOURCE:** 2005 Immunization Information System Annual Report.

<sup>\*</sup> Participation is defined as having two or more recorded vaccinations.

<sup>&</sup>lt;sup>†</sup>Chicago, Illinois; Houston, Texas; New York City, New York; Philadelphia, Pennsylvania; and San Antonio, Texas.

<sup>\*</sup> Participation is defined as having two or more vaccinations recorded in + an immunization information system.

<sup>&</sup>lt;sup>+</sup>Grantees include 50 states, five cities, and DC, funded under section 317b of the Public Health Service Act.

 <sup>&</sup>lt;sup>5</sup>Chicago, Illinois (34%–66%); DC (67%–94%); Houston, Texas (34%–66%); New York City, New York (95%–100%); Philadelphia, Pennsylvania (95%–100%); San Antonio, Texas (67%–94%); United States (56%).

provider sites submitted vaccination data to an IIS; eight (14%) reported submission of vaccination data by 81%–94% of public provider vaccination sites. Eight (14%) grantees (Arkansas, Connecticut, DC, Mississippi, North Dakota, Philadelphia, San Antonio, and South Dakota,) reported that >95% of private vaccination provider sites submitted vaccination data to an IIS; five (9%) (Arizona, Delaware, Michigan, Oregon, and Wisconsin) reported data submission by 81%–94% of private provider vaccination sites.

**Reported by:** BC Canavan, M Kurilo, MPH, Oregon Dept of Human Svcs. T Moss, Georgia Registry Immunization Transactions and Svcs. R McLaren, MS, K Berry, MD, District of Columbia Dept of Health. C Thomas, Trey Industries, Locust Grove, Virginia. B Rasulnia, MPH, J Kelly, G Urquhart, MPH, Immunization Svcs Div, National Center for Immunization and Respiratory Diseases (proposed), CDC.

**Editorial Note:** In 2005, approximately 56% of U.S. children aged <6 years participated in an IIS, an increase from 48% in 2004, or approximately 2 million more children (*3*). In addition, IIS private-provider–site participation increased from 39% in 2004 to 44% in 2005.

IISs are being used increasingly as a decision-making tool for immunization programs and health-care providers to generate patient reminders and recalls, perform vaccine inventory management and distribution tasks, conduct routine public health surveillance, conduct school assessments, and identify clusters of undervaccinated children. Data from IISs have been used by immunization programs to make more effective and timely decisions. For example, during a routine Vaccines for Children Program site visit, the Oregon Immunization Program discovered that one vaccine (diphtheria and tetanus toxoids and acellular pertussis vaccine [DTaP]) was not being stored at proper temperatures in a pediatric clinic. According to data in the Oregon IIS, approximately 3,100 children had received 1 or more doses of DTaP or TriHIBit®9 (Sanofi Pasteur, Swiftwater, Pennsylvania) vaccine during the period in which the vaccines were improperly stored. Within 8 days, Oregon IIS staff members had coordinated with the clinic to compile the necessary information to conduct a patient recall. An estimated 3,100 families received notices to return for revaccination; 1,280 (41%) children returned to the clinic and received 1 or more doses of vaccine containing diphtheria and tetanus within 90 days after the notice was mailed.

The ability to share and exchange data with other information systems also has increased the usefulness of IISs for health insurance providers, health department clinics, Medicaid, and schools. The ability to use IIS data to comply with schoolentry laws has ensured up-to-date vaccinations for children and improved the quality of IIS data. In 2005, a total of 38 (75%) grantees provided elementary schools with access to IIS data to monitor, document, and comply with school entry laws.

In 2003, the Georgia Registry of Immunization Transactions and Services (GRITS) formed a partnership with the Houston Hot Shots Coalition in Houston County, Georgia, to increase use of GRITS in kindergarten classes and elementary schools in Houston County. Before 2003, annual kindergarten up-to-date vaccination rates for the Houston County Board of Education ranged from 67% to 90%. After implementing the partnership's recommendation to use GRITS for the 2003–04 school year audit, the rate for all 22 elementary schools was 100%. As a result of this success, the coalition presented the school superintendent with a proposal that GRITS be the official school-vaccination record for all students and that all students entering Houston County schools have their vaccination records validated by GRITS. The coalition proposal was approved by the school superintendent and implemented for the 2006-07 school year.

In DC, the Department of Health collaborated with DC Public Schools (DCPS) and other partners on the DC School Immunization Project, which successfully monitored and documented school vaccination rates for the estimated 54,000 children enrolled in DCPS. The project objectives were to 1) use local partnerships to link traditional and high-technology quality-improvement strategies to overcome limited resources and achieve higher school vaccination rates; 2) identify and track vaccination levels for all public school children; and 3) use the IIS for quality improvement and improvement of overall vaccination rates and accuracy. DCPS provided the IIS with weekly enrollment files, which kept IIS staff members informed about new enrollees and allowed them to update vaccination rates. In addition, health insurance providers in the DC area provided the IIS with electronic enrollment data monthly, and the IIS provided updated information on the vaccination status of enrollees, including a list, by school, of enrolled students who met vaccination requirements. Before 2001, IISs were used for assessing DCPS vaccination compliance for entry to school and middle schools only. After implementing schoolwide policies to use IISs, the proportion of students with documentation of DCPS-required vaccinations increased from 40% in June 2001 to 96% in June 2006. At the end of the 2005-2006 school year, 155 (98%) of 158 schools in DCPS had compliance rates of  $\geq$ 90%, and 28 had rates of 100%.

The findings in this report are subject to at least two limitations. First, data from the 2005 IISAR are self-reported, which might have resulted in reporting bias. Second, because some grantees did not report data, the IIS participation rates for

<sup>&</sup>lt;sup>9</sup> Combination *Haemophilus influenzae* B conjugate vaccine (ACTHib<sup>®</sup> [Sanofi Pasteur]) reconstituted with DTaP (Tripedia<sup>®</sup> [Sanofi Pasteur]).

children aged <6 years and providers might be underestimated or overestimated.

Immunization programs that use IIS data have improved the quality of vaccination activities in various settings in Oregon, Georgia, and DC. These examples illustrate the usefulness of IIS data for assessing program activities and measuring progress toward reaching immunization program goals. As participation in IIS increases and data quality improves, data from IIS will improve the effectiveness and efficiency of immunization programs throughout the United States.

#### References

- National Vaccine Advisory Committee. Development of community and state-based immunization registries: report of the National Vaccine Advisory Committee (NVAC). Atlanta, GA: US Department of Health and Human Services, CDC; 1999. Available at http://www.cdc.gov/nip/ registry/pubs/nvac.htm.
- Linkins RW. Immunization registries: progress and challenges in reaching the 2010 national objective. J Public Health Manag Pract 2001; 7:67–74.
- CDC. Immunization information system progress—United States, 2004. MMWR 2005;54:1156–7.

### Brief Report

## Influenza Vaccination Coverage Among Children Aged 6–23 Months — Six Immunization Information System Sentinel Sites, United States, 2005–06 Influenza Season

Beginning with the 2004-05 influenza season, the Advisory Committee on Immunization Practices (ACIP) recommended that all children aged 6-23 months receive influenza vaccinations annually (1). Other children recommended to receive influenza vaccinations include those aged 6 months-18 years who have certain high-risk medical conditions, those on chronic aspirin therapy, those who are household contacts of persons at high risk for influenza complications, and, since 2006, all children aged 24–59 months (1). Previously unvaccinated children aged <9 years need 2 doses administered at least 1 month apart to be considered fully vaccinated (1). This report assesses influenza vaccination coverage among children aged 6-23 months during the 2005-06 influenza season by using data from six immunization information system (IIS) sentinel sites. The findings demonstrate that vaccination coverage with 1 or more doses varied widely (range: 6.6% to 60.4%) among sites, with coverage increasing from the preceding influenza season in four of the six sites. However, <23% of children in five of the sites were fully vaccinated, underscoring the need for increased measures to improve the proportion of children who are fully vaccinated.

This report is based on data from IISs, which are confidential, computerized systems that maintain vaccine administration information and have other important capabilities (e.g., vaccine management, adverse event reporting, assistance in disease surveillance activities, and linkages with electronic data sources). CDC collaborates with IIS sentinel sites in five states (Arizona, Michigan, Minnesota, Montana, and Oregon) and the District of Columbia to promote population-based analysis of IIS data for immunization program assessment and evaluation. The sites represent geographically contiguous counties or census tracts for which IIS data are collected on ≥10,000 children aged <6 years, representing >95% of the population in that age group in that area. Sentinel sites also have approximately 90% of the vaccine provider locations in the geographic area as IIS participants.

Vaccination coverage was estimated for September 1, 2005– March 31, 2006, among children who were aged 6–23 months during the entire period (i.e., children born during April 1, 2004–March 1, 2005). Two measures of vaccination coverage were reported: 1) receipt of 1 or more doses of influenza vaccine during September 2005–March 2006 and 2) receipt of 2 or more doses of influenza vaccine (i.e., fully vaccinated). Children were considered fully vaccinated if they had 1) received no dose of influenza vaccine before September 1, 2005, but then received 2 doses during September 1, 2005– March 31, 2006, or 2) received 1 or more doses of influenza vaccine before September 1, 2005, and then received 1 or more additional doses during September 1, 2005–March 31, 2006.

Vaccination coverage with 1 or more doses among children aged 6–23 months ranged from 6.6% to 60.4% in the sentinel sites (Table). Percentages of children who were fully vaccinated ranged from 2.3% to 43.4%. Compared with the 2004–05 influenza season (2), vaccination coverage with 1 or more doses increased at four sentinel sites and decreased at two sites (Table). The percentage of children who were fully vaccinated remained the same at one sentinel site, decreased at one site, and increased at four sites.

National Immunization Survey (NIS) estimates for the 2005–06 influenza season are not yet available; however, previous IIS estimates of influenza vaccination coverage among children have been similar to NIS results (Table) (*3*). During the 2005–06 season, the disparity in vaccination coverage among the IIS sentinel sites was likely a result of the degree of vaccine promotion in each locale and the likelihood of reporting the administered doses to the IIS. For example, health-care workers at Site F indicated that anecdotal evidence and previous NIS estimates suggest that the low reported vaccination coverage likely reflects underreporting of influenza vaccination to the IIS rather than the actual coverage.

2004-05 influenza season 2005-06 influenza season 1 or more doses 1 or more doses of influenza vaccine **Fully vaccinated** of influenza vaccine **Fully vaccinated IIS sentinel IIS sentinel IIS sentinel IIS sentinel** sites NIS sites NIS sites sites % (95% CI\*) % (95% CI) **IIS sentinel site** % % % % А (21.0 - 32.4)38.5 22.6 30.0 26.7 13.1 12.4 (8.4 - 16.4)В 34.5 (26.4 - 41.4)(12.9 - 24.5)38.9 20.4 33.9 15.4 18.7 С 26.5 17.9 32.5 (24.4 - 40.6)11.4 16.9 (10.4 - 23.4)33.4 D 50.6 47.6 (41.1 - 60.1)18.5 25.1 (16.9 - 33.3)42.9 5.7 Е 35.6 30.3 (22.0 - 38.6)18.5 13.1 (7.3 - 18.9)60.4 43.4 F 8.2 31.1 (23.3-38.9) 2.1 12.2 (7.1 - 17.3)6.6 2.3

TABLE. Influenza vaccination coverage levels among children aged 6–23 months — six immunization information system (IIS) sentinel sites (2004–05 and 2005–06 influenza seasons) and National Immunization Survey (NIS) (2004–05 influenza season), United States

\* Confidence interval.

Although limitations exist regarding the use of IIS data, state health departments should consider the IIS as a means for rapidly assessing influenza vaccination coverage. Prompt reporting of influenza vaccinations to the IIS can enable local or statewide assessments during the current influenza season, aiding measures to increase the proportion of fully vaccinated children.

**Reported by:** K Fredrickson, MPH, Arizona Dept of Health Svcs. RP McLaren, MS, District of Columbia Dept of Health. KS Enger, MPH, Michigan Dept of Community Health. KWhite, MPH, Minnesota Dept of Health. B Kirsch, Montana Dept of Public Health and Human Svcs. BC Canavan, Oregon Dept of Human Svcs. LA Zimmerman, MPH, DL Bartlett, MPH, WG Williams, MPH, National Center for Immunization and Respiratory Diseases (proposed), CDC.

#### References

- 1. CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices. MMWR 2006; 55(No. RR-10).
- Zimmerman L, Bartlett D, Gosney K, Enger K, Williams W. Influenza vaccination coverage among children aged 6–23 months, 2004–2005: data from immunization information system sentinel site projects [Abstract 47]. Proceedings and abstracts of the 40th National Immunization Conference; March 6–9, 2005; Atlanta, GA.
- CDC. Childhood influenza-vaccination coverage—United States, 2004–05 influenza season. MMWR 2006;55:1062–5.



did not have coverage because of cessation of Medicaid benefits. Less than 3% of persons without health insurance did not have coverage because of a change in marital status or death of a parent. **SOURCE:** Adams PF, Barnes PM. Summary health statistics for the U.S. population: National Health Inteview

SOURCE: Adams PF, Barnes PM. Summary health statistics for the U.S. population: National Health Interiew Survey, 2004. National Center for Health Statistics. Vital Health Stat 2006;10(229). Available at http://www.cdc.gov/nchs/data/series/sr\_10/sr10\_229.pdf.

TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending December 9, 2006 (49th Week)\*

	Current	Cum	5-year	Total	cases rer	orted for	r previou	s vears	
Disease	week	2006	averaget	2005	2004	2003	2002	2001	States reporting cases during current week (No.)
Anthrou	week	1	average	2000	2004	2000	2002	2001	otates reporting cases during current week (NO.)
Antiniax	_	1	0	_		_	2	23	
foodborno		12	1	10	16	20	20	20	
infont	_	76	1	19	97	20	20	07	
other (wound & unspecified)	1	10	2	33	20	22	09	10	CA(1)
Brucollosic	1	102	1	100	11/	104	125	126	CA (1)
Chancroid		27	2	17	30	54	67	38	
Cholera		6	0	8	5	2	2	3	
Cyclosporiasis§		11/	2	716	171	75	156	1/7	
Diphtheria	_			/10		1	130	2	
Domestic arboviral diseases <sup>§,¶</sup>								2	
California serogroup	_	7	1	80	112	108	164	128	
eastern equine	_	_	0	21	6	14	10	9	
Powassan	_	_	_	1	1	_	1	Ň	
St Louis	_	3	0	13	12	41	28	79	
western equine	_	_	_						
Fhrlichiosis <sup>§,</sup>									
human granulocytic	17	420	9	790	537	362	511	261	CT (1) NY (16)
human monocytic	7	385	5	521	338	321	216	142	NY (7)
human (other & unspecified)	_	171	1	122	59	44	23	6	
Haemophilus influenzae **			•	122	00		20	0	
invasive disease (age <5 vrs):									
serotype b	_	8	0	9	19	32	34	_	
nonserotype b	_	78	2	135	135	117	144	_	
unknown serotype	1	189	3	217	177	227	153	_	GA (1)
Hansen disease <sup>§</sup>	_	68	2	88	105	95	96	79	
Hantavirus pulmonary syndromes	_	29	0	29	24	26	19	8	
Hemolytic uremic syndrome, postdiarrheal§	2	225	4	221	200	178	216	202	NC (1), OK (1)
Hepatitis C viral, acute	13	705	28	751	713	1.102	1.835	3.976	NY (1), MI (3), MO (1), DC (1), NC (1), TN (1), LA
(1), OK (1), TX (1), CA (2)						, -	,	-,	$\langle n \rangle \langle n \rangle = \langle n \rangle = \langle n \rangle = \langle n \rangle \langle n \rangle \langle n \rangle$
HIV infection, pediatric (age <13 yrs) <sup>§,††</sup>	_	52	6	380	436	504	420	543	
Influenza-associated pediatric mortality §.§§	_	40	0	45	_	Ν	N	N	
Listeriosis	13	683	13	892	753	696	665	613	RI (1), NY (7), PA (1), IN (1), NC (1), FL (1), AL (1)
Measles <sup>11</sup>	_	45	0	66	37	56	44	116	
Meningococcal disease, invasive***:									
A, C, Y, & W-135	1	207	5	297	—	_	_	_	TX (1)
serogroup B	2	123	4	157	—	_	_	_	IN (1), FL (1)
other serogroup	1	21	0	27	_	—	—	_	MN (1)
Mumps	9	6,221	5	314	258	231	270	266	PA (1), OH (2), KS (2), MD (2), FL (1), AL (1)
Plague	_	16	0	8	3	1	2	2	
Poliomyelitis, paralytic	—	—	—	1	—	—	—	—	
Psittacosis§		19	0	19	12	12	18	25	
Q fever <sup>§</sup>	1	142	1	139	70	71	61	26	MN (1)
Rabies, human	_	2	0	2	7	2	3	1	
Rubella	_	9	0	11	10	7	18	23	
Rubella, congenital syndrome	_	1	0	1	_	1	1	3	
SARS-CoV <sup>s.TTT</sup>	_	_	_	—	_	8	N	N	
Smallpox <sup>§</sup>			_						
Streptococcal toxic-shock syndromes	1	86	2	129	132	161	118	//	MN (1)
Streptococcus pneumoniae, <sup>s</sup>									
invasive disease (age <5 yrs)	18	1,011	19	1,257	1,162	845	513	498	NY (3), OH (7), IN (1), MN (2), KS (1), DC (1),
		050	~	001	050	440	110		UK (1), AZ (2)
Syphilis, congenital (age <1 yr)	1	253	8	361	353	413	412	441	AZ (1)
Terranus		19	1	27	34	20	25	37	
I OXIC-SNOCK SYNDROME (other than streptococca	ai) <sup>3</sup> —	91	2	96	95	133	109	127	
I richinellosis	_	11	U	19	5	100	14	22	
		83	2	154	134	129	90	129	
i yprioid tever	5	253	5	324	322	356	321	368	PA (1), MD (1), WA (1), GA (2)
Vanconycin-intermediate Staphylococcus aure	us° —	3	_	2		N N	N	IN N	
vancomycin-resistant Staphylococcus aureus	_	_	_	3	1	IN	IN ₄	IN	
		_	_				1		

-: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts.

\* Incidence data for reporting year 2006 are provisional, whereas data for 2001, 2002, 2003, 2004, and 2005 are finalized.

<sup>†</sup> Calculated by summing the incidence counts for the current week, the two weeks preceding the current week, and the two weeks following the current week, for a total of 5 preceding years. Additional information is available at http://www.cdc.gov/epo/dphsi/phs/files/5yearweeklyaverage.pdf.

§ Not notifiable in all states.

Includes both neuroinvasive and non-neuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (proposed) (ArboNET Surveillance).

\*\* Data for *H. influenzae* (all ages, all serotypes) are available in Table II.

<sup>††</sup> Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (proposed). Implementation of HIV reporting influences the number of cases reported. Pediatric HIV data will not be updated monthly for the remainder of this year due to upgrading of the national HIV/AIDS surveillance data management system. Data for HIV/AIDS are available in Table IV quarterly.

§§ Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases (proposed).

No measles cases were reported for the current week.

111 Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (proposed).

<sup>&</sup>lt;sup>\*\*\*</sup> Data for meningococcal disease (all serogroups and unknown serogroups) are available in Table II.

(49III WEEK)"			Chlamyd	lia†			Coccio	lioidomv	cosis			Crv	otosporio	liosis	
		Pre	vious				Prev	vious				Pre	vious		
Reporting area	Current week	<u>52 v</u> Med	veeks Max	Cum 2006	Cum 2005	Current week	52 w Med	eeks Max	Cum 2006	Cum 2005	Current week	52 v Med	veeks Max	Cum 2006	Cum 2005
United States	11.832	19.355	35.170	898.911	903.206	211	151	1.643	7.591	4.544	51	68	594	4.898	7.353
New England Connecticut Maine <sup>§</sup> Massachusetts New Hampshire Rhode Island <sup>§</sup> Vermont <sup>§</sup>	749 347 22 283 19 57 21	638 172 42 294 38 61 19	1,550 1,214 65 606 71 107 41	31,231 9,004 2,109 14,468 1,872 2,745 1,033	30,744 9,273 2,130 13,609 1,736 3,091 905	N 	0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	N N N N	N N - - - N	2 1 - - 1	4 0 1 1 0 0	37 34 6 14 5 6 5	279 34 42 88 49 14 52	344 79 30 148 37 13 37
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	1,537 — 792 398 347	2,375 358 499 698 752	3,696 496 1,727 1,567 1,075	111,947 16,110 23,280 36,139 36,418	111,899 18,096 22,491 36,436 34,876	N N N	0 0 0 0	0 0 0 0	N N N N	N N N N	5 	11 0 3 2 4	444 3 441 7 17	559 11 171 107 270	3,176 57 2,708 144 267
E.N. Central Illinois Indiana Michigan Ohio Wisconsin	601 — 423 89 89	3,146 975 392 649 632 383	12,578 1,697 478 9,888 1,424 516	144,974 47,285 18,078 32,592 29,250 17,769	154,425 47,823 18,917 27,273 41,090 19,322	  N     N	1 0 0 0 0	3 0 3 2 0	43 — 37 6 N	11 	2 1 1	15 1 2 5 5	105 18 18 8 33 53	1,189 140 98 134 344 473	1,596 158 85 107 758 488
W.N. Central lowa Kansas Minnesota Missouri Nebraska <sup>§</sup> North Dakota South Dakota	681 95 130  268 97 5 86	1,164 157 150 237 439 103 32 51	1,455 225 269 347 614 176 61 116	55,725 7,782 6,785 10,697 21,326 5,082 1,555 2,498	55,585 6,958 6,971 11,565 21,144 4,806 1,562 2,579	N N     N N N N N N N N N N N N N N N	0 0 0 0 0 0 0	12 0 12 1 0 0 0	1 N 1 N N N	4 N 3 1 N N	5  - 5  -  -	12 1 3 2 1 0 1	77 28 8 22 21 16 4 7	823 170 78 222 177 92 9 75	596 120 39 134 244 28 1 30
S. Atlantic Delaware District of Columbia Florida Georgia Maryland <sup>§</sup> North Carolina South Carolina <sup>§</sup> Virginia <sup>§</sup> West Virginia	3,012 107 42 750 12 201 800 583 473 44	3,725 68 53 961 700 337 613 347 439 60	4,943 92 137 1,182 2,142 487 1,772 1,452 840 227	176,630 3,408 2,723 45,940 31,616 16,902 31,885 18,653 22,535 2,968	165,280 3,203 3,571 40,607 29,703 17,518 29,573 17,636 20,863 2,606	1 N   N   1 N N N N N N N N N N N N N N	0 0 0 0 0 0 0 0 0	1 0 0 0 1 0 0 0 0	5 N   N   5 N N N N N	2 N N 2 N N N N	23 — 13 6 1 3 —	15 0 6 5 0 1 1 1	67 3 2 32 18 3 11 13 6 3	1,115 15 527 254 20 96 123 55 10	729 6 16 338 143 32 88 24 65 17
E.S. Central Alabama <sup>§</sup> Kentucky Mississippi Tennessee <sup>§</sup>	1,486 100 691 205 490	1,420 412 163 374 512	1,941 756 613 807 605	70,155 19,634 8,729 17,876 23,916	65,862 15,846 7,968 20,077 21,971	N N N	0 0 0 0	0 0 0 0	N N N	N N N	12 12 —	3 1 1 0 0	12 10 5 3 5	198 103 35 16 44	222 25 146 3 48
<b>W.S. Central</b> Arkansas Louisiana Oklahoma Texas <sup>§</sup>	1,026 153 122 — 751	2,177 155 228 233 1,459	3,605 335 607 2,159 1,897	102,032 7,762 12,007 11,724 70,539	103,612 8,072 16,241 10,819 68,480	  N	0 0 0 0	1 0 1 0 0	1 1 N	N N N	1  1	4 0 1 2	44 2 9 4 35	324 20 67 40 197	225 6 82 44 93
Mountain Arizona Colorado Idaho <sup>§</sup> Montana <sup>§</sup> Nevada <sup>§</sup> New Mexico <sup>§</sup> Utah Wyoming <sup>§</sup>	784 408 — 47 207 122 —	1,025 359 141 43 46 87 193 94 27	1,839 881 395 191 195 432 339 176 54	48,529 17,918 5,480 2,333 2,413 5,078 9,402 4,652 1,253	59,341 19,824 14,585 2,620 2,168 6,981 7,774 4,282 1,107	123 121 N N 	108 105 0 0 1 0 1 0	452 448 0 0 4 3 3 2	5,095 4,967 N N 52 15 59 2	2,898 2,794 N N 63 19 19 3	1    1	2 0 1 0 0 0 0 0	38 3 7 1 26 1 5 3 11	332 24 68 132 11 29 20 48	137 10 50 14 21 11 17 11 3
Pacific Alaska California Hawaii Oregon <sup>§</sup> Washington	1,956 103 1,200  255 398	3,325 81 2,623 100 174 348	5,079 152 4,231 135 315 604	157,688 3,777 123,843 4,845 8,478 16,745	156,458 4,038 121,397 5,223 8,354 17,446	87 	43 0 43 0 0 0	1,179 0 1,179 0 0 0	2,446  2,446  N N	1,629  1,629  N  N	  	1 0 0 1 0	52 1 14 1 7 38	79  4  71 	328 3 194 1 69 61
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	U U 198	0 0 17 93 5	46 0 18 190 16	U U 4,331 178	U U 806 3,772 196	U U N	0 0 0 0	0 0 0 0	U U N	U U N	U U N	0 0 0 0	0 0 0 0	U U N	U U N

TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending December 9, 2006, and December 10, 2005 (4

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-\* Incidence data for reporting year 2006 is provisional. \* Chlamydia refers to genital infections caused by *Chlamydia trachomatis*. § Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

•			Giardias	is			G	onorrhe	ea		Hae	<i>mophilu</i> All age	s influen es, all sei	<i>zae</i> , invas rotypes	sive
	Current	Prev 52 w	ious eeks	Cum	Cum	Current	Prev 52 w	/ious /eeks	Cum	Cum	Current	Prev 52 v	vious	Cum	Cum
Reporting area	week	Med	Max	2006	2005	week	Med	Max	2006	2005	week	Med	Max	2006	2005
United States	198	317	1,029	15,939	18,062	3,910	6,584	14,136	312,983	311,967	23	39	142	1,870	2,085
New England	9	22	75	1,117	1,587	140	108	288	5,268	5,537	_	2	19	140	152
Connecticut	_	2	31	276	347	71	42	241	2,129	2,376	—	0	9	44	44
Massachusetts	_	3	13	357	701	50	47	8 86	2.301	2,386	_	1	4	19 52	72
New Hampshire	_	Õ	9	28	61	2	3	9	178	167	_	Ó	2	10	8
Rhode Island <sup>†</sup>	9	1	25	111	107	16	9	19	476	417	_	0	7	6	7
		3	12	0.114	0.001		1	4	00 100	00 005		0	2	9	9
New Jersev	37	62 8	254	3,114	3,261	323	102	1,014	4,580	32,265 5,378	5	0	30	358	408
New York (Upstate)	25	24	227	1,190	1,135	108	121	455	5,919	6,639	1	3 3	27	130	113
New York City	1	15	29	826	849	112	175	378	9,177	9,773	2	2	6	85	75
Pennsylvania	11	15	32	759	843	103	222	394	10,522	10,475	2	3	8	143	134
E.N. Central	20	48 8	82 21	2,258	3,150 742	329	1,264	7,047	59,450 18 051	62,771 18 883		5	14	262 47	349 117
Indiana	Ν	0	0	N	N	_	161	248	7,991	7,653	2	1	11	75	62
Michigan	4	14	37	639	754	231	261	5,880	13,894	11,117	3	0	3	23	23
Ohio Wisconsin	16	16 9	32 40	778 482	760 894	45 53	301 131	683 172	13,418	19,600 5,518	2	2	6 4	86 31	104 43
W N Central	18	27	260	1 659	2 171	204	372	444	17 610	17 766	1	2	15	144	111
lowa		5	15	268	271	21	35	62	1,737	1,537	_	ō	1	2	
Kansas	2	3	11	191	198	32	42	124	1,902	2,421	_	0	2	15	17
Minnesota	2 12	1 Q	238	488 507	954 499	132	189	105	2,749	3,320	1	0	9	32	43
Nebraska†	2	2	20	111	114	15	27	56	1,332	1,083	_	0	2	9	15
North Dakota	_	0	7	17	19		3	.7	120	116	_	0	3	9	3
South Dakota	_	1	5	77	116	4	7	15	351	329	_	0	0	—	_
S. Atlantic	41	50	95	2,493	2,603	1,136	1,623	2,334	79,057	73,218	6	10	24	499	496
District of Columbia	2	1	4	62	53	41	35	61	1,400	2.037	_	0	2	8	10
Florida	32	20	44	1,073	908	302	458	547	21,676	18,921	—	3	9	156	127
Georgia	2	11	28	532	702	9	349	1,014	15,990	13,912	3	2	6	98	105
Maryland	3 N	3	11	203 N	199 N	96 226	126	189	6,184 16 449	6,607 14 234	2	1	5 9	66 53	71
South Carolina <sup>†</sup>	_	1	7	97	104	254	150	704	8,409	8,237		1	3	33	34
Virginia <sup>†</sup>	_	8	50	455	532	162	132	288	6,237	7,753	_	1	8	65	51
West Virginia	2	0	6	35	48	11	18	43	943	677	_	0	4	19	26
E.S. Central	8	10	42	542	406	595	576	867	28,428	26,494	—	2	7	107	111
Kentucky	N	0	0	320 N	N N	268	59	180	3,205	2.814	_	0	1	5	12
Mississippi	_	0	Ō	_	_	86	149	435	7,053	6,725	_	Ō	1	4	_
Tennessee <sup>†</sup>	2	4	12	222	218	177	192	238	9,114	8,154	—	1	4	66	82
W.S. Central	1	5	31	283	309	527	898	1,430	44,241	42,331	3	1	15	65	112
Arkansas	1	2	8	127	81	85	81	142	4,034	4,220	_	0	2	7	7
Oklahoma	_	2	24	121	168		86	764	4.367	4.303	3	1	14	47	60
Texas <sup>†</sup>	Ν	0	0	Ν	N	331	568	915	28,278	24,796	_	0	0	—	8
Mountain	17	30	66	1,577	1,469	176	222	552	11,023	12,839	1	4	8	183	203
Arizona	3	3	36	152	142	111	92	201	4,433	4,626	_	1	7	82	98
Lolorado Idaho†	_	9	33	173	508 148	_	43	85	2,067	3,036	_	0	4	48	40
Montana <sup>†</sup>	_	2	11	106	72	2	3	20	184	143	_	õ	Ó	_	
Nevadat	_	1	8	85	108	51	25	194	1,615	2,723	_	0	1	1	14
New Mexico <sup>†</sup>	13	1	6 25	67 446	87 377	12	32	65 25	1,667	1,446	1	0	4	25 17	26
Wyoming <sup>†</sup>	1	1	4	37	27	_	3	6	113	79	_	0	1	4	9
Pacific	47	59	202	2,896	3,106	480	794	967	37,708	38,746	_	2	15	112	143
Alaska	1	1	17	97	108	14	11	24	517	560	_	0	2	9	27
California Hawaii	35	43	105	2,058	2,206	348	657	834	31,083	32,242	_	0	9	27	56
Oregon <sup>†</sup>	1	8	4 14	365	400	31	28	29 49	025 1.273	1,469	_	1	6	55	9 51
Washington	10	7	90	330	331	84	76	142	4,010	3,494	_	Ó	4	2	_
American Samoa	U	0	0	U	U	U	0	2	U	U	U	0	0	U	U
C.N.M.I.	U	0	0	U	U	U	0	0	U	U	U	0	0	U	U
Buerto Bico	_	U 1	0 12	78	11 250	7	5	15 16	255	90 342	_	0	1	_	14 4
U.S. Virgin Islands	_	Ö	0			_	0	5	30	45	_	õ	õ	_	_

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 9, 2006, and December 10, 2005 (49th Week)\*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-\* Incidence data for reporting year 2006 is provisional. \* Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Max: Maximum. Med: Median.

				Hepat	titis (viral,	acute), by ty	/pe	_					alex-II.	-i	
		Bro	A				Brov	B				Le	gionello	SIS	
	Current	52 v	veeks	Cum	Cum	Current	52 w	eeks	Cum	Cum	Current	52 w	/eeks	Cum	Cum
Reporting area	week	Med	Max	2006	2005	week	Med	Max	2006	2005	week	Med	Max	2006	2005
United States	35	66	245	3,146	3,992	54	85	574	3,920	4,540	24	40	127	2,277	2,102
New England	3	3	20	158	438	1	2	8	90	146	1	2	12	117	146
Connecticut	1	1	2	40	49	-	0	3	29	46	—	0	9	49	34
Massachusetts	_	0	2	51	281	_	0	2 5	22 14	50	_	0	2	9 27	66
New Hampshire	—	Ō	16	37	80	_	Ō	2	13	29	_	Ō	1	1	9
Rhode Island <sup>†</sup>	2	0	4	16	15	—	0	4	9	3	1	0	10	23	21
	_	0	2	0	0	_	0		007	0	_	10	2	0	9
New Jersev		6 1	5	333	622 147	4	8	55 8	397	624 231	5	13	47	849 96	735
New York (Upstate)	_	2	14	89	94	1	1	43	57	56	3	6	30	311	204
New York City	-	2	10	111	283		2	5	84	125		2	16	132	113
	1	1	10	02	90	5	5	9	070	212	2	5	19	450	300
E.N. Central	_	6 1	13	285	357 121	0	8	24	379 60	540 152	4	9	25	453	431
Indiana	—	0	5	28	19	3	0	17	56	40	_	Ō	4	35	32
Michigan	- 1	2	7	107	121	2	3	6	134	180		3	11	135	115
Wisconsin	_	1	4	52 37	50 46	_	2	2	121	45	4	0	5	226	34
W.N. Central	2	2	30	123	88	3	3	22	152	260	_	1	15	75	93
lowa	_	0	2	11	19	_	Ō	3	16	27	_	0	3	10	8
Kansas Minnocoto	—	0	5	26	16	—	0	2	9	29	_	0	2	6	3
Minnesota Missouri	_	1	29	43	31	2	1	6	23 81	29 144	_	0	3	24	20 29
Nebraska <sup>†</sup>	2	0	2	19	18	1	0	3	20	24	_	0	2	9	4
North Dakota South Dakota	_	0	2	8	1	_	0	0	3	7	_	0	1		21
S Atlantic	12	10	20	532	602	17	23	66	1 007	1 207	11	0	10	121	200
Delaware		0	29	12	6		23	4	46	30		0	2	12	18
District of Columbia	_	0	2	8	4		0	2	9	11	1	0	5	33	12
Florida Georgia	8	4	13	208	276	11	8	19	396 166	460	5	3	9	153	107
Maryland <sup>†</sup>	_	1	6	61	74		2	10	140	149	2	2	7	89	108
North Carolina	5	0	20	99	82	_	0	23	148	150	3	0	5	37	33
South Carolina <sup>1</sup>	_	0	3 11	23 57	42 82	1	2	18	64	146 125	_	0	1	4 67	15 46
West Virginia	_	Ó	3	6	4	1	0 0	18	51	40	_	ò	3	15	21
E.S. Central	1	2	8	124	233	3	7	19	375	348	_	2	9	99	84
Alabama <sup>†</sup>	_	0	3	20	43	_	2	12	137	87	_	0	2	13	13
Mississippi	_	0	5 1	9	24 19	_	1	5 4	37	67 49	_	0	5 2	39	31
Tennessee <sup>†</sup>	1	1	5	64	147	3	2	7	135	145	—	1	7	44	37
W.S. Central	_	6	77	326	454	7	17	315	766	607	_	0	32	49	44
Arkansas	—	0	9	38	19	—	1	3	50	68	—	0	3	3	6
Oklahoma	_	0	4	22	5	1	0	17	71	44	_	0	6	4	3
Texas <sup>†</sup>	—	5	73	257	368	6	12	295	611	426	—	0	26	35	28
Mountain	5	5	17	253	318	1	3	16	132	178	_	2	8	117	94
Arizona	5	2	16	154	173	—	0	3	8	<u> </u>	—	1	4	38	23
Idaho†	_	0	2	9	21	_	0	2	13	16	_	0	3	11	20
Montana <sup>†</sup>	_	0	3	11	10	_	0	7	_	3	_	0	1	6	6
Nevada <sup>†</sup> New Mexico <sup>†</sup>	_	0	2	11 14	23	_	1	5	30	48	_	0	2	85	20
Utah	_	Ő	2	13	19	_	0	5	27	36	_	Ő	6	27	13
Wyoming <sup>†</sup>	_	0	1	3	1	1	0	1	1	2	_	0	0	_	4
Pacific	9	19	163	1,012	790	12	11	61	532	530	3	1	9	84	76
Alaska California	8	0 15	0 162	909	4 668	8	U 8	3 41	.9 391	7 354	.3	0 1	0	84	1 72
Hawaii	_	0	3	12	24		0	1	6	9		ò	Ő		,2
Oregon <sup>†</sup>		1	5	43	44		1	5	76	96	N	0	0	N	N
vvasnington	1	0	13	48	50	4	U	18	50	64		0	0		
American Samoa	U	0	0	U	1	U	0	0	U		U	0	0	U	U
Guam	_	0	0		2		0	0		18		0	0	_	
Puerto Rico	—	0	6	30	64	—	0	8	31	51	—	0	1	2	_
U.S. Virgin Islands	—	0	0			—	0	0				0	0	_	—

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending December 9, 2006, and December 10, 2005 (49th Week)\*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-\* Incidence data for reporting year 2006 is provisional. \* Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

			Lyme dis	ease				Malaria	1		
		Pre	evious				Prev	vious			
	Current	52 w	veeks	Cum	Cum	Current	52 w	eeks	Cum	Cum	
Reporting area	week	Med	Max	2006	2005	week	Med	Max	2006	2005	
United States	154	230	2,153	16,464	20,754	8	26	125	1,202	1,319	
New England	13	27	780	2,856	3,885	1	0	11	47	70	
Connecticut	11	9	753	1,661	996	—	0	3	11	20	
Maine <sup>†</sup>	_	2	34	280	243	—	0	1	4	5	
Massachusetts		0	12	33	2,311	_	0	3	19	36	
Rhode Island <sup>†</sup>	2	4	94	235	240 37	1	0	3	10	2	
Vermont <sup>†</sup>	_	1	15	96	53		Ö	1	1	1	
Mid. Atlantic	88	128	1,176	9.257	11.760	_	5	13	269	343	
New Jersey	_	22	173	1,918	3,330	_	Ō	3	28	76	
New York (Upstate)	59	58	1,150	3,907	3,829	_	1	11	46	49	
New York City		1	18	163	394	_	3	9	150	183	
Pennsylvania	29	38	231	3,209	4,207	_	1	4	45	35	
E.N. Central	—	10	150	1,443	1,723	_	2	7	117	144	
Indiana	_	0	3	21	30	_	0	3	11	8	
Michigan	_	1	5	53	60	_	Ō	2	16	22	
Ohio	—	1	5	42	55	_	0	3	27	26	
Wisconsin	—	10	146	1,327	1,451	_	0	2	18	15	
W.N. Central	40	6	169	812	913	1	0	32	61	46	
lowa	_	1	8	87	91	—	0	1	2	8	
Minnesota	40	2	167	698	799	1	0	30	39	11	
Missouri		0	2	11	15	_	Õ	1	6	17	
Nebraska <sup>†</sup>	—	0	2	11	3	_	0	1	5	3	
North Dakota		0	3	-		—	0	1	1	_	
South Dakota		0			2	_	0				
S. Atlantic	11	28	116	1,810	2,222	4	7	15	310	295	
District of Columbia	3	0	20	430	8	_	0	2	5	11	
Florida	3	1	5	56	44	1	ĩ	4	60	61	
Georgia	_	0	_1	7	6	2	1	6	80	48	
Maryland <sup>†</sup>	5	13	73	877	1,204	1	1	5	68	98	
South Carolina <sup>†</sup>	_	0	2	29 18	20	_	0	2	20 10	10	
Virginia <sup>†</sup>	_	4	28	294	244	_	ĩ	9	52	31	
West Virginia		0	44	14	17	—	0	1	2	3	
E.S. Central	1	0	3	36	36	—	0	3	24	30	
Alabama†	1	0	3	16	3	—	0	2	11	6	
Kentucky Mississioni	_	0	2	/	5	_	0	1	4	10	
Tennessee <sup>†</sup>	_	0	2	12	28	_	0	2	5	14	
W.S. Central		0	3	18	76	_	2	31	83	119	
Arkansas	_	õ	1	_	4	_	ō	1	2	6	
Louisiana	—	0	0	_	3	_	0	1	5	5	
Oklahoma Toxast		0	0	19		—	0	2	7	10	
	_	0	5	10	09	_	1	29	09	90	
Arizona		0	3	25	21	—	1	9	67	52	
Colorado	_	0	1	1		_	0	2	16	24	
Idaho†	_	Õ	2	6	2	_	õ	1	1	_	
Montana <sup>†</sup>	—	0	0	_	_	—	0	1	2	_	
Nevada <sup>†</sup>	_	0	1	2	3	—	0	1	4	3	
Utah	_	0	1	2	2	_	0	2	17	3 7	
Wyoming <sup>†</sup>	_	õ	1	1	3	_	õ	0	_	2	
Pacific	1	4	13	207	118	2	4	13	224	220	
Alaska	_	0	1	3	4	_	0	4	23	6	
California	1	3	12	187	83	1	4	10	148	165	
Hawaii Oregon <sup>†</sup>	N	0	0	N 14	N 01	_	0	2	8	18	
Washington	_	0	∠ 3	3	21 10	1	0	2 5	33	18	
American Samoa	П	0	0	LI L	U.	U	0	0	LI I	LI LI	
C.N.M.I.	Ŭ	ŏ	õ	Ŭ	Ŭ	Ŭ	õ	ŏ	Ŭ	Ŭ	
Guam		0	0			_	0	0			
Puerto Rico	N	0	0	N	N	_	0	1	1	4	
U.U. VII YII I ISIdHUS		0	0		_	_	0	0			

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending December 9, 2006, and December 10, 2005 (49th Week)\*

Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-\* Incidence data for reporting year 2006 is provisional. Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

				Mening	gococcal d	isease, inva	sive								
			All serogr	oups			Sero	ogroup u	nknown				Pertus	sis	
	Current	Pre 52 v	vious veeks	Cum	Cum	Current	Prev	ious eeks	Cum	Cum	Current	52 w	/ious /eeks	Cum	Cum
Reporting area	week	Med	Max	2006	2005	week	Med	Max	2006	2005	week	Med	Max	2006	2005
United States	16	19	85	1,010	1,122	12	12	58	659	696	134	257	2,877	12,093	21,902
New England	—	1	3	43	68	_	0	2	28	23	13	23	83	1,092	1,456
Connecticut Maine <sup>†</sup>	_	0	2	10	14	_	0	2	3	1	_	1	5 11	45 92	75 54
Massachusetts	_	ŏ	2	15	31	_	Ő	2	15	6	_	16	31	594	1,082
New Hampshire	_	0	2	6	12	—	0	2	6	12	2	2	36	182	124
Rhode Island <sup>1</sup> Vermont <sup>†</sup>	_	0	1	2	4 5	_	0	0	_	2	10	0	17 14	68 111	36
Mid. Atlantic	3	3	13	157	146	3	2	11	123	112	29	36	137	1,716	1,280
New Jersey		0	2	16	31		0	2	16	31	_	3	13	185	182
New York (Upstate)	1	1	/ 4	36	40 24	1	0	5 4	6 58	14 24	23	15 1	123	817 64	509 105
Pennsylvania	2	1	4	47	51	2	Ó	4	43	43	6	13	26	650	484
E.N. Central	1	2	12	118	153	_	1	7	84	121	28	38	133	1,791	3,673
Illinois Indiana	- 1	0	4	18	33	_	0	4	18	33		5	22	231	887
Michigan	_	0	3	20	34	_	0	1	9	18	1	10	38	584	304
Ohio	—	1	4	43	43	—	1	3	35	37	18	12	29	584	1,106
Wisconsin	_	0	2	14	25	_	0	2	14	25		3	11	168	1,063
W.N. Central Iowa	3	1	4	61 20	80 15	2	0	2	21	34	18	23 5	552 22	1,145 257	3,820
Kansas	_	õ	1	2	10	_	Ő	1	2	10	9	6	25	304	488
Minnesota	3	0	2	16	16	2	0	1	6	6	3	0	485	164	1,084
Missouri Nebraska†	_	0	2	14	28	_	0	1	2	13	2	6	42	280 94	574 286
North Dakota	_	Õ	1	1	1	_	Õ	1	1	1		ō	25	26	139
South Dakota	_	0	1	2	4	_	0	0	_	—	_	0	4	20	179
S. Atlantic	5	4	14	185	209	4	1	7	79	95	23	18	46	951	1,360
District of Columbia		0	1	2	4 5		0	1	2	4	_	0	3	6	8
Florida	2	1	6	69	77	1	0	5	25	32	2	4	9	199	197
Georgia Manuland <sup>†</sup>	- 1	0	3	15	17		0	3	15	17	1	0	3	25	48
North Carolina	1	0	11	32	32	1	0	3	12	9	11	0	22	188	118
South Carolina <sup>†</sup>	_	0	2	21	13	_	0	2	9	8	_	3	11	167	398
Virginia⁺ West Virginia	_	0	4	18 9	33	_	0	1		14	6	2	27	195 46	329
E.S. Central	2	1	4	46	55	2	1	4	37	44	5	6	28	395	493
Alabama <sup>†</sup>	2	Ó	2	11	5	2	Ó	1	8	3	2	2	19	145	79
Kentucky	_	0	2	11	18	—	0	2	11	18	_	1	5	54	147
Tennessee <sup>†</sup>	_	0	2	20	25	_	0	2	4 14	16	2	3	10	42 154	207
W.S. Central	1	1	23	57	104		0	6	24	27	1	17	360	749	2.281
Arkansas	_	0	3	10	15	—	Ō	2	7	3	_	1	21	75	292
Louisiana	—	0	2	6 11	30	—	0	1	3	7	—	0	1	13	51
Texas <sup>†</sup>	1	0	16	30	45	_	0	4	14	15	1	14	215	642	1,935
Mountain	_	1	5	65	84	_	0	4	24	23	13	48	230	2,432	3,875
Arizona	—	0	3	17	31	—	0	2	10	10	4	7	177	459	927
Colorado Idahot	_	0	2	20 4	17	_	0	1	2	5	_	12	40	/12 84	1,299
Montana <sup>†</sup>	_	ŏ	1	5	_	_	Ő	1	2	_	_	2	9	109	582
Nevada <sup>†</sup>	_	0	1	4	13	—	0	0	_	2	_	0	9	55	50
New Mexico	_	0	1	6 5	5 12	_	0	0	3	4		14	8 39	819	578
Wyoming <sup>†</sup>	_	Ő	2	4		_	Ő	2	4	_	_	1	8	75	50
Pacific	1	5	29	278	223	1	5	25	239	217	4	30	1,334	1,822	3,664
Alaska California	1	0	1	3 170	120		0	1	3 170	4	1	1 01	15	64 1 201	139
Hawaii	_	0	2	9	11		3 0	2	9	6	_	∠ı 1	6	روحر, 1 78	1,909
Oregon <sup>†</sup>	_	0	7	62	50	_	0	4	43	50		2	8	100	617
Washington	—	0	25	32	19		0	11	12	18	3	5	195	289	838
American Samoa	U	0	0	—	_	U	0	0	U	U	U	0	0	U	U
Guam		0	0	_	1	<u> </u>	0	0	<u> </u>	1		0	0	<u> </u>	2
Puerto Rico	_	Õ	1	4	7	_	Õ	1	4	7	_	Õ	1	2	6
U.S. Virgin Islands	_	0	0	—	—	—	0	0	—	—	_	0	0	—	—

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 9, 2006, and December 10, 2005 (49th Week)\*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-\* Incidence data for reporting year 2006 is provisional. \* Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

<u>,</u>		Ra	abies, ani	mal		Roo	ky Mour	itain spo	tted feve	r		S	almonell	osis	
	0	Prev	ious	0	0	0	Previ	ous	0	0	0	Pre	evious	0	0
Reporting area	week	<u>52 w</u> Med	<u>еекs</u> Мах	2006	2005	week	 Med	Max	2006	2005	week	Med	Max	2006	2005
United States	57	121	239	5,972	5,561	7	38	246	2,027	1,678	572	779	2,291	39,686	41,632
New England Connecticut Maine <sup>†</sup> Massachusetts New Hampshire Rhode Island <sup>†</sup> Vermont <sup>†</sup>	9 5 1  3	12 3 2 3 1 0 1	26 14 8 17 5 3 5	640 203 117 178 51 24 67	675 197 61 321 13 28 55	N 	0 0 0 0 0 0	2 0 1 1 2 0	3 	8  6 1 1	11 3 2 5 1	22 0 15 3 0 1	473 465 10 53 25 17 6	1,732 465 116 782 205 89 75	2,064 446 160 1,100 172 95 91
<b>Mid. Atlantic</b> New Jersey New York (Upstate) New York City Pennsylvania	14 N 14 	27 0 10 0 16	71 0 24 5 56	1,564 N 527 37 1,000	952 N 537 28 387	2 — — 2	1 0 0 1	6 1 2 3 3	82 7 5 23 47	97 30 1 7 59	42  27  15	84 14 24 23 29	272 48 233 50 67	4,793 803 1,251 1,170 1,569	4,846 931 1,154 1,155 1,606
<b>E.N. Central</b> Illinois Indiana Michigan Ohio Wisconsin	1 — 1 	2 0 1 0 0	18 7 2 5 9 0	162 46 11 47 58 N	170 50 12 38 70 N		0 0 0 0 0	6 2 1 1 4 1	42 5 8 3 25 1	41 11 6 21 2	71  15 2 54 	100 22 15 18 23 17	187 51 67 34 56 27	4,747 1,005 813 898 1,257 774	5,471 1,769 601 907 1,284 910
W.N. Central lowa Kansas Minnesota Missouri Nebraska <sup>†</sup> North Dakota South Dakota	1 1 	6 1 0 1 0 0 1	20 7 5 6 0 7 4	301 57 79 40 66  24 35	308 	  	2 0 0 2 0 0 0	15 1 1 2 11 5 1 0	210 5 1 4 175 25 —	154 7 5 2 128 7 5	31 5 8 16 2 —	47 8 7 11 14 3 0 2	107 26 16 60 35 9 46 7	2,519 426 355 685 722 184 28 119	2,451 399 348 532 760 215 38 159
S. Atlantic Delaware District of Columbia Florida Georgia Maryland <sup>†</sup> North Carolina South Carolina <sup>†</sup> Virginia <sup>†</sup> West Virginia	28  -  20  5  - 3	38 0 5 7 9 3 12 2	183 0 167 24 13 22 11 27 7	2,073 — 167 233 318 493 166 585 111	2,005  201 247 367 451 212 459 68	1  1   	20 0 1 1 17 0 1 0	94 3 5 6 87 5 13 2	1,123 21 1 22 49 75 817 33 102 3	840 7 2 13 85 71 473 71 111 7	172 2 90 29 8 31 7 5	219 3 1 95 32 12 33 17 20 2	395 10 4 176 71 29 130 51 57 19	10,704 142 62 4,541 1,686 686 1,562 950 941 134	12,224 120 54 5,130 1,876 777 1,606 1,397 1,086 178
E.S. Central Alabama <sup>†</sup> Kentucky Mississippi Tennessee <sup>†</sup>	2 2 —	4 1 0 2	16 8 4 2 9	252 81 29 4 138	146 78 17 5 46	3 3 —	6 2 0 0 3	31 11 1 1 22	393 133 3 4 253	288 72 3 18 195	77 68  9	58 20 8 11 14	153 84 23 42 32	3,150 1,280 411 720 739	2,846 691 470 886 799
<b>W.S. Central</b> Arkansas Louisiana Oklahoma Texas <sup>†</sup>	 	11 0 0 1 10	34 5 0 9 29	563 31 61 471	829 33 — 75 721	 	1 0 0 0	161 10 1 154 4	117 51 56 36 25	216 128 6 52 30	23 12 	82 15 13 8 35	922 47 42 48 839	4,033 896 789 480 1,868	4,148 698 888 389 2,173
Mountain Arizona Colorado Idaho <sup>†</sup> Montana <sup>†</sup> Nevada <sup>†</sup> New Mexico <sup>†</sup> Utah Wyoming <sup>†</sup>	1  -  -  -  -  -	3 2 0 0 0 0 0 0 0	27 10 25 2 1 2 1 2	207 137  25 14 2 10 11 8	266 165 18 12 15 14 10 15 17		0 0 0 0 0 0 0 0 0	6 6 1 3 2 0 2 2 1	50 10 2 14 2 	32 17 4 3 1 4 4 3	34 27 — 1 6	50 17 12 3 2 3 4 5 1	88 67 30 9 10 20 15 15 4	2,424 842 579 164 122 176 233 265 43	2,299 653 557 146 134 187 243 297 82
<b>Pacific</b> Alaska California Hawaii Oregon <sup>↑</sup> Washington	1 1 — U	4 0 3 0 0 0	12 4 11 0 4 0	210 16 169  25 U	210 1 202 7 U	1 1 	0 0 0 0 0	1 0 1 0 1 0	7 5 2 N	2  -   2 N	111 4 87 - 3 17	113 1 89 5 8 8	426 7 292 18 16 124	5,584 71 4,391 252 397 473	5,283 57 4,057 276 394 499
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	U U 	0 0 1 0	0 0 6 0	U U 68	U U 65	U U N	0 0 0 0	0 0 0 0	U U N	U U N	U U —	0 0 1 4 0	0 0 3 35 0	U U 233	7 U 43 616 —

 TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 9, 2006, and December 10, 2005

 (49th Week)\*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: No U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to- \* Incidence data for reporting year 2006 is provisional. \* Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

	Shia	a toxin-p	roducina	E. coli (ST	EC)†		Sh	niaellosis	5		Strepto	coccal d	isease. ii	ivasive. c	aroup A
	Current	Prev 52 w	ious eeks	Cum	Cum	Current	Prev 52 w	ious	Cum	Cum	Current	Prev 52 w	ious eeks	Cum	Cum
Reporting area	week	Med	Max	2006	2005	week	Med	Max	2006	2005	week	Med	Max	2006	2005
United States	51	51	297	2,787	3,097	199	257	1,013	12,766	14,539	60	92	282	4,450	4,235
<b>New England</b> Connecticut Maine <sup>§</sup> Massachusetts New Hampshire Rhode Island <sup>§</sup>	 	2 0 1 0	80 79 8 9 3 2	254 79 43 82 25 8	213 58 29 84 16 7	2 — — 2	3 0 2 0 0	69 63 2 11 2 3	226 63 3 128 11 15	310 54 15 187 17 20	U U U	3 0 2 0 0	15 2 6 9 3	185 U 18 101 44 8	272 97 14 124 18 9
Vermont <sup>§</sup>	—	Õ	2	2	19	_	Ő	2	6	17	_	Ő	2	14	10
<b>Mid. Atlantic</b> New Jersey New York (Upstate) New York City Pennsylvania	21 — — 13	5 0 0 2	107 3 103 4 12	327 3 10 34 136	350 73 133 17 127	8 6 2	16 3 4 5 1	72 34 60 13 6	795 242 220 247 86	1,186 297 259 398 232	9 	18 2 5 2 6	43 8 32 8 13	859 122 292 141 304	826 174 232 162 258
<b>E.N. Central</b> Illinois Indiana Michigan Ohio Wisconsin	12 1 1 	10 1 1 3 2	56 7 8 6 18 39	616 75 81 86 196 178	619 136 70 91 166 156	11 6 5	20 7 2 3 3 3	37 18 18 8 14 9	939 316 158 140 188 137	1,137 386 172 231 129 219	15 — 3 1 11	14 3 2 3 4 1	44 11 11 12 19 4	740 144 109 204 231 52	853 286 97 201 181 88
W.N. Central owa Kansas Winnesota Missouri Nebraska <sup>§</sup> North Dakota South Dakota	9 1 5 1 —	9 2 0 3 1 1 0 0	33 8 4 27 10 8 15 5	521 116 29 231 84 55 — 49	516 99 53 168 96 61 8 31	20 1 	34 2 3 9 2 0 6	77 10 20 24 69 14 18 22	1,623 112 136 233 629 119 103 291	1,667 96 259 87 971 146 4 104	3 N 2 1 	5 0 1 0 1 1 0 0	57 0 52 52 4 5 1	329 N 53 149 77 31 11 8	268 N 39 102 66 22 13 26
S. Atlantic Delaware District of Columbia Florida Georgia Maryland <sup>§</sup> North Carolina South Carolina <sup>§</sup> Virginia <sup>§</sup> West Virginia	5  - 4  1 2 	9 0 2 2 1 2 0 0	39 3 1 29 6 8 7 2 8 5	460 12 3 91 84 98 108 9 -	394 9 1 88 49 75 61 12 95 4	48 — 32 14 1 — —	57 0 27 19 2 1 1 2 0	142 2 76 74 10 21 9 9	3,187 10 17 1,505 1,200 123 151 72 104 5	2,327 11 15 1,152 637 99 187 102 123 1	23   1 6 3 5 8   	21 0 5 4 0 1 2 0	44 2 16 12 26 6 11 6	1,091 10 18 280 233 194 157 54 118 27	880 6 11 238 193 166 118 33 93 22
E.S. Central Alabama <sup>§</sup> Kentucky Mississippi Tennessee <sup>§</sup>	 	1 0 1 0 0	12 5 12 0 4	93 47 93  24	174 29 75 8 62	7 6 1	13 4 4 2 2	81 72 15 9 12	906 432 227 91 156	1,154 214 312 96 532	1 N 1	3 0 0 0 3	11 0 5 0 9	184 N 35 — 149	169 N 32  137
<b>W.S. Central</b> Arkansas Louisiana Oklahoma Texas <sup>§</sup>	  2	1 0 0 2	52 7 1 17 44	76 33 — 43 110	114 13 22 29 50	40 4  3 33	36 2 1 2 30	596 9 25 286 308	1,735 119 138 129 1,349	3,486 59 136 614 2,677	3 1 1 1	7 0 0 2 4	58 5 2 14 43	346 26 8 98 214	301 22 113 166
Mountain Arizona Colorado Idaho <sup>§</sup> Montana <sup>§</sup> Nevada <sup>§</sup> New Mexico <sup>§</sup> Utah Wyoming <sup>§</sup>		5 2 1 1 0 0 0 1 0	16 13 8 7 0 5 1 14 3	306 124 102 81  22 4 120 20	300 30 82 50 16 24 24 64 10	23 17 — — — 1 5	24 11 4 0 1 2 1 0	86 34 15 3 13 20 15 6 8	1,396 697 232 15 56 103 164 80 49	912 483 163 17 5 63 132 44 5	5 3     2	11 6 3 0 0 1 1 0	77 57 8 2 0 0 7 7 1	594 317 130 8 — 68 67 4	553 233 169 3 — 82 61 5
<b>Pacific</b> Alaska California Hawaii Oregon <sup>§</sup> Washington	4   4	2 0 0 2 2	50 0 18 2 14 32	134 — 18 109 116	417 — 147 13 155 102	40 40 —	39 0 31 1 2	148 2 104 4 31 43	1,959 9 1,657 43 115 135	2,360 12 2,051 32 124 141	1 1 N N	2 0 2 0 0	9 0 9 0 0	122 — 122 N N	113  113  N  N
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	U U —	0 0 0 0	0 0 0 0	U U 	U U 2	U U 	0 0 0 0	0 0 2 0	U U 13	7 U 20 9	U U N	0 0 0 0	0 0 0 0	U U N	U U N

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending December 9, 2006, and December 10, 2005 (49th Week)\*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: No N: Not notifiable.

Cum: Cumulative year-to-date counts.

Max: Maximum.

Med: Median.

<sup>1</sup> Incidence data for reporting year 2006 is provisional.
 <sup>1</sup> Incidence data for reporting year 2006 is provisional.
 <sup>1</sup> Incidence *E. coli* O157:H7; Shiga toxin positive, serogroup non-0157; and Shiga toxin positive, not serogrouped.
 <sup>8</sup> Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

· · ·	Strepto	<i>coccus pı</i> Drug r	n <i>eumonia</i> resistant, a	<i>e</i> , invasive all ages	disease	Sypl	hilis, prin	nary and	seconda	ry		Varice	ella (chic	kenpox)	
	0	Prev	vious	0	0	0	Previ	ous	0	0	0	Prev	/ious	0	0
Reporting area	week	Med	еекs Max	2006	2005	week	Med	Max	2006	2005	week	Med	<u>/eeks</u> Max	2006	2005
United States	84	50	333	2,353	2,416	108	175	334	8,462	8,056	850	835	2,857	39,628	27,887
New England	1	0	24	37	221	3	4	17	197	202	17	32	113	1,415	5,046
Connecticut	U	0	7	U	93	2	0	11	53	46	U	0	50	U 151	1,595
Massachusetts	_	0	2 5	9	98	1	2	2 6	109	117	_	2	20 26	94	299
New Hampshire	—	0	0			_	0	2	12	15	8	6	47	473	327
Rhode Island <sup>†</sup>	1	0	11	13 15	18 12	_	0	2	13	22 1	9	0 12	0 50	697	651
Mid Atlantic	1	3	15	162	195	_	21	35	1 044	961	95	102	184	4 663	4 639
New Jersey	Ň	0	0	N	N	_	3	8	150	127		0	0	-,000	-,000
New York (Upstate)	1	1	10	60	74	—	3	14	139	73	—	0	0	—	_
Pennsylvania		2	9	102	121	_	5	23 12	241	574 187	95	102	184	4,663	4,639
E.N. Central	45	11	41	566	596	9	17	39	821	877	298	288	587	14,158	5,743
Illinois	_	0	3	17	35	—	7	23	381	501	—	1	7	68	95
Indiana Michigan	2	2	21 4	155 18	178 42	1	1	5 19	86 106	58 80	100	105	475 185	475 4572	3 686
Ohio	43	6	32	376	341	6	3	8	183	202	198	136	420	8,388	1,523
Wisconsin	N	0	0	Ν	Ν	2	1	4	65	36	_	10	52	655	439
W.N. Central	2	1	191	106	43 N	3	5	12	248	241	42	27	98	1,673	648
Kansas	N	0	0	N	N	2	0	3	26	18	5	3	24	313	
Minnesota	_	0	191	60		—	0	2	29	68		0	0		
Missouri Nebraska†	_2	1	3	41	35	_	3	8	155	141 4	35	20	82	1,231	450
North Dakota	_	0	0	_	3	_	0	1	1	1	_	Ő	17	45	65
South Dakota	_	0	3	4	3	1	0	3	13	1	2	1	10	84	133
S. Atlantic	34	24	53	1,233	1,019	27	42	186	1,989	2,025	61	91	860	4,184	2,596
Delaware	1	0	03	 27	3 15	_	0	2	1/ 117	10	_	1	65	63 46	29
Florida	17	13	36	682	545	7	15	23	688	672	_	ŏ	0		
Georgia	16	6	29	420	345		7	147	362	461	_	0	0	—	_
North Carolina	N	0	0	N	N	6 8	5 5	14	273	302 260	_	0	0	_	_
South Carolina <sup>†</sup>	_	0	0	_	_	2	1	5	65	82	22	19	53	1,046	600
Virginia <sup>†</sup>	N	0	0	N 104	N 111	3	3	17	179	132	14	30	812	1,598	825
E Control	- 1	2	19	107	170	10	12	26	670	460	20	20	70	1,401	201
Alabama <sup>†</sup>	N	0	0	N	N	6	5	19	305	160	3	2	70	152	291
Kentucky	_	0	1	_	32	1	1	9	67	52	N	0	0	Ν	N
Mississippi Tennesseet	1	03	0 13	137	1 146		1	7 13	69 237	47 203	N	0	1	2 N	N
W S Central	_	0	5	21	113	27	20	54	1 / 82	1 18/	260	180	1 757	10.673	6 4 4 2
Arkansas	_	0	3	12	14	1	29	6	76	48	35	12	110	926	38
Louisiana		0	4	9	99	18	4	27	286	265	_	1	8	66	122
Texas <sup>†</sup>	N N	0	0	N	N	8	22	ь 34	68 1,052	833	234	170	0 1,647	9,681	6,282
Mountain	_	2	9	91	50	14	8	25	403	400	65	59	137	2,710	2,482
Arizona	N	ō	Ő	N	Ň	9	3	16	180	158	_	0	0		
Colorado	N	0	0	N	N	—	1	3	44	45	—	30	76	1,388	1,734
Montana†		0	1	IN	IN	_	0	1	2	20	_	0	13	24	_
Nevada <sup>†</sup>	_	Ō	0	_	_	5	2	12	105	105	_	Ō	0	_	
New Mexico <sup>†</sup>	—	0	0	40		_	1	5	62	55		4	34	347	211
Wyoming <sup>†</sup>	_	1	9 4	43	25	_	0	0				0	11	59	53
Pacific	_	0	0	_	_	13	34	51	1.600	1.704		0	0	_	
Alaska		0	0			_	0	4	9	6	_	0	0	—	
California Hawaii	N	0	0	N	Ν	5	29	43	1,378	1,507	N	0	0	N	
Oregon <sup>†</sup>	N	0	0	N	N	_	0	6	24	36	N	0	0	N	N
Washington	N	0	0	Ν	Ν	8	2	10	172	144	Ν	0	0	Ν	N
American Samoa	_	0	0	—	—	U	0	0	U	U	U	0	0	U	U
C.N.M.I. Guam	_	0	0	_	_	U	0	0	U	U	U	0	0	U	U 721
Puerto Rico	N	0	0	N	N	6	3	10	137	206	_	7	47	321	679
U.S. Virgin Islands	_	0	0	_	_	_	0	0	_	_		0	0	_	

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending December 9, 2006, and December 10, 2005 (49th Week)\*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-\* Incidence data for reporting year 2006 is provisional. Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

			Neuroinvas	ive		 -	No	n-neuroin	vasive		
		Bros	vioue				Broy	vioue	140110		
	Current	52 M	lous	Cum	Cum	Current	52 w	lous	Cum	Cum	
Reporting area	week	Med	Max	2006	2005	week	Med	Max	2006	2005	
United States	HOUR		60	474	1 101	HOUR	4	200	0 454	1 600	
United States	_	0	60	471	1,191	_	I	383	2,454	1,683	
New England	_	0	2	3	9	—	0	2	3	4	
Connecticut		0	2	3	4		0	1	2	2	
Massachusetts	_	0	0	_	4	_	0	1	1	2	
New Hampshire	_	õ	ŏ	_	_	_	Ő	Ö	<u> </u>		
Rhode Island§	_	Ō	Ō	_	1	_	Ō	Ō	_	_	
Vermont <sup>§</sup>	_	0	0	—	—	—	0	0	_	—	
Mid. Atlantic	_	0	2	6	47	_	0	4	10	22	
New Jersey		Õ	ō	_	3	_	Õ	1	2	3	
New York (Upstate)	_	0	1	3	19	—	0	1	3	5	
New York City	—	0	1	2	11	_	0	2	4	3	
Pennsylvania	_	0	1	1	14	_	0	1	1	11	
E.N. Central	_	0	16	74	259	_	0	22	99	156	
Illinois	_	0	10	44	137	—	0	19	70	115	
Indiana	—	0	2	7	11	—	0	2	7	12	
Nichigan	—	0	3	14	54	_	0	1	2	8 15	
Wisconsin	_	0	3 0	9	40 11	_	0	3	a II	6 1	
	—	0	0		11		0		3	0	
W.N. Central	—	0	16	81	169	_	0	79	477	463	
iuwa Kansas	_	0	3	9	14	_	0	4 2	13	23 N	
Minnesota	_	0	5	19	18		0	7	35	27	
Missouri	_	ŏ	1	4	17	_	ŏ	2	12	13	
Nebraska§	_	0	7	20	55	_	0	37	212	133	
North Dakota	_	0	3	8	12	—	0	28	117	74	
South Dakota	_	0	5	21	36	_	0	22	75	193	
S. Atlantic		0	1	5	34	_	0	4	7	29	
Delaware	_	0	0	_	1	_	0	0		1	
District of Columbia	_	0	0	—	3	—	0	1	1	2	
Florida	_	0	0	—	10	_	0	0	_	11	
Georgia		0	0		9		0	3	5	11	
North Carolina	_	0	1	5	4	_	0	0		2	
South Carolina <sup>§</sup>	_	0	0	_	5	_	0	0	_		
Virginia§		Õ	õ	_	_	_	Õ	õ		1	
West Virginia	—	0	0	_	—	N	0	0	N	N	
E.S. Central	_	0	4	14	65		0	16	94	38	
Alabama <sup>§</sup>	_	õ	1	1	6	_	Ő	0		4	
Kentucky	_	0	0	_	5	_	0	1	1	_	
Mississippi	_	0	3	9	39	—	0	16	91	31	
Tennessee <sup>§</sup>	_	0	2	4	15	—	0	2	2	3	
W.S. Central	_	0	19	81	157	_	0	26	208	150	
Arkansas	_	0	0	_	13	_	0	2	5	15	
Louisiana		0	0			_	0	9	81	54	
Oklahoma		0	1	1	1/		0	4	18	14	
Texas <sup>3</sup>	_	0	19	80	127		0	15	104	07	
Mountain	—	0	29	161	145	—	0	222	1,321	240	
Arizona	—	0	5	21	52	—	0	12	58	61	
Loorado Idabo§	_	0	11	34 16	21	_	0	51 151	269	85	
Montana§	_	0	2	11	3 8	_	0	7	21	17	
Nevada§	_	õ	3	13	14	_	õ	13	75	17	
New Mexico <sup>§</sup>	_	Ō	1	2	20	_	Ō	1	5	13	
Utah	—	0	5	28	21	_	0	17	101	31	
Wyoming <sup>§</sup>	—	0	3	6	6	_	0	8	40	6	
Pacific	_	0	6	46	306	_	0	45	235	581	
Alaska	_	0	0	_		_	0	0		_	
California	_	0	6	44	305	—	0	33	182	575	
Hawaii	_	0	0	_		—	0	0		_	
Uregon <sup>s</sup> Weshington	—	0	1	2	1		0	12	50	6	
washington	_	U	U	_	_	_	U	2	3	_	
American Samoa	U	0	0	U	U	U	0	0	U	U	
C.N.M.I.	U	0	0	U	U	U	0	0	U	U	
Guam Puerto Bico	_	0	0		_	_	0	0	_	_	
LLS Virgin Jelande	_	0	0	_	_	_	0	0	_	_	
e.e. mgin ioiunuo		0	0				0	0			

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 9, 2006, and December 10, 2005 (49th Week)\* West Nile virus disease<sup>†</sup>

C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. -: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts.

\* Incidence data for reporting year 2006 is provisional. <sup>†</sup> Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (proposed) (ArboNET Surveillance). <sup>§</sup> Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

Med: Median.

Max: Maximum.

TADLE III. Dealiis III 122 0.3. cilles. Week chuinu December 3. 2000 (4311 Wee	TABLE III	. Deaths in	122 U.S.	cities.	* week ending	a December 9	. 2006	(49th Week
--	-----------	-------------	----------	---------	---------------	--------------	--------	------------

	All causes, by age (years)						All causes, by age (years)								
Reporting Area	All Ages	<u>≥</u> 65	45-64	25-44	1-24	<1	P&l⁺ Total	Reporting Area	All Ages	<u>&gt;</u> 65	45-64	25-44	1-24	<1	P&l⁺ Total
New England	540	382	106	28	12	12	44	S. Atlantic	1,376	819	363	. 121	48	23	80
Boston, MA	142	101	29	4	4	4	15	Atlanta, GA	220	122	59	23	14	2	11
Cambridge MA	33	25	5	1	1	1	3	Baltimore, MD	235	127	64 24	29	12	3	24
Fall River, MA	28	21	6	_	_	1	4	Jacksonville, Fl	172	105	47	15	3	2	7
Hartford, CT	52	36	9	4	3	_	5	Miami, FL	96	59	19	12	5	1	2
Lowell, MA	31	22	3	5	1	—	2	Norfolk, VA	57	37	17	_	_	3	2
Lynn, MA	9	6	2	1	_	—		Richmond, VA	56	27	21	7	1	_	2
New Bedford, MA	18	14	2	2	_	_	1	Savannah, GA	59	37	17	5			1
Providence Bl	20 75	54	14	3	1	3	2	Tampa Fl	177	39 119	42	5 10	4	2	13
Somerville, MA	5	4	1	_	_	_	_	Washington, D.C.	100	53	33	6	3	3	3
Springfield, MA	50	29	12	4	2	3	3	Wilmington, DE	12	8	3	1	_	_	1
Waterbury, CT	17	11	5	1	—	—	1	E.S. Central	990	641	246	76	17	10	87
Worcester, MA	44	35	9	_	_	_	_	Birmingham, AL	200	129	48	19	4	_	10
Mid. Atlantic	2,251	1,551	472	142	47	35	119	Chattanooga, TN	104	66	29	7	_	2	4
Albany, NY	54	37	16	1		_	5	Knoxville, TN	109	80	22	3	3	1	3
Allentown, PA	27	25	1		1	_	2	Lexington, KY	60 177	41	15	10	1	1	5
Camden N.I	04 31	18	21	5 4		2	_	Mobile Al	101	59	40 28	10	2	1	30
Elizabeth. NJ	20	8	6	4	2	_	_	Montgomery, AL	50	38	9	3			7
Erie, PA	55	47	5	1	_	2	2	Nashville, TN	189	119	47	13	5	5	21
Jersey City, NJ	47	33	12	1	1	—	6	W S Central	1 492	980	331	121	33	27	78
New York City, NY	1,100	752	246	69	17	12	48	Austin, TX	107	69	29	5	1	3	12
Newark, NJ Paterson, NJ	37	16	8	12	_	1	2	Baton Rouge, LA	64	35	_	23	6	_	_
Philadelphia PA	290	185	72	17	12	4	15	Corpus Christi, TX	77	51	17	6	3	—	3
Pittsburgh, PA§	42	28	9	1	1	3	4	Dallas, TX	223	140	49	22	7	5	11
Reading, PA	30	25	4	1	—	_	1	EI Paso, TX Fort Worth TX	127	85	30	10	3		8
Rochester, NY	153	111	20	11	8	3	16	Houston TX	279	172	78	18	4	7	8
Schenectady, NY	24	20	3	1	_	-		Little Rock, AR	Ű	Ū	Ŭ	Ŭ	U	Ů	Ŭ
Svracuse NY	41 137	29 105	20	6	1	5	3	New Orleans, LA <sup>1</sup>	U	U	U	U	U	U	U
Trenton, NJ	32	19	6	3	2	2	_	San Antonio, TX	235	162	48	14	5	6	16
Utica, NY	16	15	1	_	_	_	_	Shreveport, LA	64 176	105	12	12			11
Yonkers, NY	18	14	2	2	—	—	1	Tuisa, OK	170	125	30	12		2	
E.N. Central	2,220	1,440	538	147	40	55	128	Mountain	1,301	844	292	90	38	34	82
Akron, OH	51	27	20	—	3	1	1	Boise ID	66	49	11	10	2	3	2
Canton, OH	36	24	10		_	2		Colorado Springs, CO	88	64	14	6	2	2	3
Cincinnati OH	351	194	20	44	4	9	25	Denver, CO	87	57	20	5	5	_	4
Cleveland, OH	233	163	46	10	5	9		Las Vegas, NV	314	201	80	23	6	4	19
Columbus, OH	256	159	68	15	5	9	20	Ogden, UI	27	18	5	1	1	2	10
Dayton, OH	154	107	34	7	4	2	8	Phoenix, AZ Pueblo, CO	201	29	49	10		14	12
Detroit, MI	152	81	51	16	3	1	5	Salt Like City, UT	146	88	36	13	5	4	12
Evansville, IN	39	31	8 15	6	2	_	3	Tucson, AZ	161	107	40	7	3	4	12
Garv. IN	19	10	8	1		_	_	Pacific	1.460	1.023	318	74	20	25	122
Grand Rapids, MI	55	43	7	2	_	3	2	Berkeley, CA	13	10	2	1	_	_	3
Indianapolis, IN	200	127	47	16	3	7	12	Fresno, CA	U	U	U	U	U	U	U
Lansing, MI	54	41	10	2	1	_	5	Glendale, CA	U	U	U	Ŭ	U	U	U
Milwaukee, WI	91 40	60	25	6		1	3	Honolulu, HI	84 64	54	21	5	2	2	3
Rockford, IL	53	39	8	4	2	_	4	Los Angeles, CA	U		U	U U	Ű	Ū.	U
South Bend, IN	64	46	12	4	1	1	4	Pasadena, CA	22	14	5	2	1	_	2
Toledo, OH	90	60	27	2	—	1	8	Portland, OR	162	112	36	8	1	5	10
Youngstown, OH	79	65	12	1	_	1	5	Sacramento, CA	198	143	43	9	2	1	17
W.N. Central	672	452	138	48	26	8	37	San Diego, CA	183	128	34	8	4	9	17
Des Moines, IA	70	54	12	3	1	_	3		252	185	53	0 10	3	1	23
Duluth, MN	31	23	6	2	—		1	Santa Cruz. CA	30	23	5	2		_	20
Kansas City, KS	35	19	10	5		1	2	Seattle, WA	142	92	35	9	2	4	18
Lincoln NF	97 48	57	19 14	13	5 1	3	3	Spokane, WA	77	59	12	6	—	—	4
Minneapolis. MN	67	39	15	6	6	1	7	Tacoma, WA	85	63	18	3	—	1	4
Omaha, NE	113	84	18	5	5	1	12	Total	12,302**	8,132	2,804	847	281	229	777
St. Louis, MO	47	30	13	4	—	—	1								
St. Paul, MN	64	43	15	2	3	1	3								
wichita, KS	100	72	16	6	5	1	4	1							

U: Unavailable.

U: Unavailable. —:No reported cases. Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of ≥100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included. <sup>†</sup> Pneumonia and influenza.

<sup>1</sup>Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks. <sup>1</sup>Because of Hurricane Katrina, weekly reporting of deaths has been temporarily disrupted. \*\* Total includes unknown ages.





Beyond historical limits

\* No rubella cases were reported for the current 4-week period yielding a ratio for week 49 of zero (0).
<sup>†</sup> Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

Notifiable Disease Data Team and 122 Cities Mortality Data Team Patsy A. Hall Deborah A. Adams Rosaline Dhara Willie J. Anderson Vernitta Love Lenee Blanton Pearl C. Sharp

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format. To receive an electronic copy each week, send an e-mail message to *listserv@listserv.cdc.gov*. The body content should read *SUBscribe mmwrtoc*. Electronic copy also is available from CDC's Internet server at http://www.cdc.gov/mmwr or from CDC's file transfer protocol server at ftp://ftp.cdc.gov/pub/publications/mmwr. Paper copy subscriptions are available through the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Data are compiled in the National Center for Public Health Informatics, Division of Integrated Surveillance Systems and Services. Address all inquiries about the *MMWR* Series, including material to be considered for publication, to Editor, *MMWR* Series, Mailstop E-90, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333 or to *www.mmwrq@cdc.gov*.

All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.

☆U.S. Government Printing Office: 2007-623-038/40094 Region IV ISSN: 0149-2195